

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 July 2009 (09.07.2009)

PCT

(10) International Publication Number
WO 2009/083549 A1

(51) International Patent Classification:
C07K 1/10 (2006.01) **C07K 14/605** (2006.01)

(21) International Application Number:
PCT/EP2008/068211

(22) International Filing Date:
22 December 2008 (22.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07124141.8 28 December 2007 (28.12.2007) EP

(71) Applicant (for all designated States except US): **NOVO NORDISK A/S** [DK/DK]; Novo Alle, DK-2880 Bagsværd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAU, Jesper Færgeman** [DK/DK]; Dybedalsvej 27, DK-3520 Farum (DK). **ANDERSEN, Asser Sloth** [DK/DK]; Onsbjerg Allé 13, DK-2730 Herlev (DK). **BLOCH, Paw** [DK/DK]; Rådalsvej 20, DK-4040 Jyllinge (DK). **LAU, Jesper** [DK/DK]; Rosenvænget 3, DK-3520 Farum (DK). **GARIBAY, Patrick William** [US/DK]; Savværksvej 3, DK-2840 Holte (DK). **KRUSE, Thomas** [DK/DK]; Tibbervangen 78, DK-2730 Herlev (DK). **NØRBY, Inga Sig Nielsen** [DK/DK]; Bregnerødvej 42, DK-3460 Birkerød (DK). **JESSEN, Claus Ulrich** [DK/DK]; Moelleengen

20, DK-3550 Slangerup (DK). **CHRISTENSEN, Caspar** [DK/DK]; Risvangen 30, DK-2700 Brønshøj (DK). **NORRILD, Jens Christian** [DK/DK]; Carl Plougs Vej 26, DK-3460 Birkerød (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES

(57) Abstract: A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis.

WO 2009/083549 A1

SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES

FIELD OF THE INVENTION

The present invention is related to a semi-recombinant method for the preparation of GLP-1 analogues and derivatives containing non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis.

BACKGROUND OF THE INVENTION

Human glucagon-like peptide-1 (GLP-1) is a 37 amino acid residue gastrointestinal hormone involved in the regulation of blood glucose metabolism, gastrointestinal secretion and metabolism and food intake. GLP-1 is originating from proglucagon which is synthesized *inter alia* in the L-cells in the distal ileum, in the pancreas and in the brain. GLP-1 stimulates insulin secretion in a glucose-dependant manner, stimulates insulin biosynthesis, promotes beta cell rescue, decreases glucagon secretion, gastric emptying and food intake. Human GLP-1 is hydrolysed to GLP-1 (7-37) and GLP-1 (7-36)-amide which are both insulinotropic agents. Pharmacological doses of GLP-1 administered to type 2 diabetic patients have been shown to significantly raise circulating insulin levels and to lower plasma glucagon levels. The actions of GLP-1 are mediated by GLP-1 receptors in the pancreas, heart, kidney, central nervous system and gastrointestinal tract. Hence, GLP-1 is expected to become very important in the treatment of diabetes.

However, native human GLP-1 is rapidly inactivated by degradation by the plasma enzyme dipeptidyl peptidase IV (DPP-IV) to a truncated GLP-1(9-36)amide metabolite, which serves as a GLP-1 receptor antagonist. This confers the peptide with a short circulating half-life.

This short circulating half-life is a problem for many diabetes patients particularly in the type 2 diabetes segment who are subject to so-called "needle-phobia", i.e. a substantial fear of injecting themselves. In the type 2 diabetes segment most patients are treated with oral hypoglycaemic agents. Since GLP-1 compounds are expected to be an injectable pharmaceutical product, the fear of

injections may become a serious obstacle for the widespread use of these clinically very promising compounds.

Hence, a range of different approaches and methods have been used for modifying the structure of GLP-1 compounds in order to provide a longer duration of action *in vivo*. Thus, a considerable effort is e.g. being made to develop analogues and derivatives of GLP-1 compounds less susceptible to DPP-IV mediated hydrolysis in order to reduce the rate of degradation by DPP-IV. WO 2006/097538, WO 2006/097536, WO 2006/037810, WO2006/005667, WO2005/058958, WO 2005/027978, WO 98/08871 and US 2001/0011071 describe various GLP-1 analogues and derivatives, including GLP analogues comprising non-proteogenic amino acids (i.e. non-natural amino acids) which may confer a certain protection against hydrolysis by DPP-IV.

Polypeptides containing only proteogenic amino acids (i.e. natural amino acids) such as native GLP-1, can be produced using recombinant techniques or via chemical synthesis. However, polypeptides also containing non-proteogenic amino acids such as N-terminally extended GLP-1 analogues, cannot currently be prepared via recombinant expression techniques in a practical way and are in general prepared via chemical synthesis. The most widely used method for peptide synthesis is solid phase peptide synthesis where the adequate protected amino acids are incorporated in a stepwise manner using a polymer as a solid support.

Solid phase peptide synthesis (SPPS) can be very efficient in the preparation of some peptides, but the use of protected amino acids in combination with the consistent use of excess of reactants makes this approach relatively expensive. In addition, each amino acid prolongation in a solid phase polypeptide synthesis requires a thorough washing procedure. Typically, incorporation of one amino acid involves up to 10 washings steps with solvents like NMP, DMF or DCM.

When polypeptides, such as insulinotropic agents, GLP-1 analogues, truncated analogues of GLP-1 and derivatives of GLP-1 are synthesized using SPPS, the formation of secondary structures during the synthesis often leads to lower

efficiency of the individual synthetic steps. As a consequence, larger peptides or peptides containing certain amino acid sequences are often produced in low purity and yields. The impurities are often deletion peptides where one or more amino acids are missing in the final sequence. These impurities can be very difficult to separate from the desired peptide, and result in a product contaminated with deletion peptides.

It is the aim of the present invention to provide an efficient and economic method for the preparation of GLP-1 analogues and derivatives which are DPP-IV protected by having non-proteogenic amino acids in the N-terminal part. The method combines the advantage of cost-efficient production of truncated GLP-1 precursor molecules, using recombinant techniques together with chemical synthesis of N-terminal extensions comprising non-proteogenic amino acids. A significant reduction of the cost of producing GLP-1 analogues or derivatives is achieved. Less expensive GLP-1 analogues and derivatives are highly desirable for maximizing the number of patients for whom treatment is available, as well as for exploiting the advantages of alternative delivery routes which have lower bioavailability than subcutaneous injection, e.g. transdermal and pulmonal delivery.

SUMMARY OF THE INVENTION

In its broadest aspect the present invention is related to a method for producing GLP-1 analogues and derivatives being DPP-IV protected by comprising one or more non-proteogenic amino acids in the N-terminal part.

Thus, in one aspect the present invention is related to a method for making GLP-1 analogues and derivatives comprising one or more non-proteogenic amino acids, said method comprising the following steps:

(i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue or derivative under suitable conditions for expression of said precursor molecule,

- (ii) separating the expressed precursor molecule from the culture broth,
- (iii) coupling an N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the expressed precursor molecule,
- (iv) isolating the resulting GLP-1 analogue or derivative by suitable means, as known in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the yeast plasmid pSA273. The plasmid contains an expression cassette comprising an *EcoRI*-*XbaI* fragment inserted into the plasmid between the transcription-promoter and the transcription-terminator of the *S. cerevisiae* TPI gene. The expression cassette encodes a fusion product composed of the MF α 1* pre-pro leader, a Lys-Arg cleavage site for the dibasic processing endopeptidase Kex2, and the GLP-1 precursor (R34)GLP-1(11-37).

Figure 2 shows the *NcoI*-*XbaI* DNA fragments encoding the GLP-1 precursors. The GLP-1 precursor amino acid sequence encoded by the DNA fragments are indicated in bold. a) (R34)GLP-1(11-37); b) Ext1-(E22,R26,R34)GLP-1(8-37)K38-Ext2 and c) Ext1-(E22,R26,R34,K37)GLP-1(8-37)-Ext2; d)(R34)GLP-1(9-37).

Figure 3 shows the *NcoI*-*XbaI* DNA fragments encoding the GLP-1 precursors and the optimized leader sequences. (34R)GLP-1(11-37) is shown as an unlimiting example. Capital letters indicate the different sequences. Optimized amino acid sequences encoded by the DNA fragments are indicated in bold. 'KR' indicates a construct with the minimal Kex2p cleavage site LysArg.

Figure 4 shows (34R)GLP-1(11-37) leader optimization as an example.

Optimization of P1 to P6: (A-F). Incorporation of proline: (H, I). Charged amino acid incorporation into P7 to P11: (M-Z, K5-7, L2-4). Constructs for downstream processing with DAPase: (G, J, K, L). Yields are given in percent relative to a

(34R)GLP-1(11-37) with the MFalpha*-leader and a simple LysArg Kex2p cleavage site.

DETAILED DESCRIPTION OF THE INVENTION

5 The present inventors have developed an economic and efficient method for preparing GLP-1 analogues and derivatives comprising one or more non-proteogenic amino acids in the N-terminal part. Thus, it has been found that recombinantly produced GLP-1 precursor molecules which contain only proteogenic amino acids can be efficiently extended in the N-terminus using a
10 non-proteogenic amino acid or a peptide containing one or more non-proteogenic amino acids, e.g. by reacting the precursor of the GLP-1 analogue with a carboxylic acid derivative, which is optionally activated, of the extension fragment.

More specifically, the present invention provides a semi-recombinant method for
15 preparation of GLP-1 analogues and derivatives containing one or more non-proteogenic amino acids in the N-terminus, including the positions 7, 8, 9 and/or 10. In addition, a useful method for derivatization of the ϵ -N of a lysine residue in the GLP-1 analogue precursor molecule via acylation is provided. Hence, the present invention combines the cost efficient production of GLP-1 analogues and
20 derivatives using recombinant techniques with the flexibility of chemical synthesis.

In the present specification, the following terms have the indicated meaning:

The term "polypeptide" and "peptide" as used herein means a compound composed of at least two constituent amino acids connected by peptide bonds.

25 The constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may be natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids. Natural amino acids which are not encoded by the genetic code are e.g., γ -carboxyglutamate, ornithine,

phosphoserine, D-alanine and D-glutamine. Synthetic amino acids comprise amino acids manufactured by chemical synthesis, i.e. D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib (α -aminoisobutyric acid), Abu (α -aminobutyric acid), Tle (tert-butylglycine), β -alanine, 3-aminomethyl benzoic acid, anthranilic acid.

The 22 proteogenic amino acids are: Alanine, Arginine, Asparagine, Aspartic acid, Cysteine, Cystine, Glutamine, Glutamic acid, Glycine, Histidine, Hydroxyproline, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine.

Thus, a non-proteogenic amino acid is a moiety which can be incorporated into a peptide via peptide bonds but is not a proteogenic amino acid. Examples of non-proteogenic amino acids are, but not limited to, γ -carboxyglutamate, ornithine, phosphoserine, the D-amino acids such as D-alanine and D-glutamine. Synthetic non-proteogenic amino acids comprise amino acids manufactured by chemical synthesis, i.e. D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib (α -aminoisobutyric acid), Abu (α -aminobutyric acid), Tle (tert-butylglycine), 3-aminomethyl benzoic acid, anthranilic acid, des-amino-Histidine, the beta analogs of amino acids such as β -alanine etc., D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^{α} -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid, α -methyl prolin, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanin.

The term "DPP-IV protected" as used herein referring to a polypeptide means a polypeptide which has been chemically modified in order to render said compound resistant to the plasma peptidase dipeptidyl peptidase-4 (DPP-IV). The DPP-IV enzyme in plasma is known to be involved in the degradation of several peptide hormones, e.g. GLP-1, GLP-2, Exendin-4 etc. Thus, a considerable effort is being

made to develop analogues and derivatives of the polypeptides susceptible to hydrolysis by DPP-IV in order to reduce the rate of degradation by DPP-IV. In one embodiment a DPP-IV protected peptide is more resistant to DPP-IV than GLP-1(7-37).

- 5 Resistance of a peptide to degradation by DPP-IV is determined by the following degradation assay:

Aliquots of the peptide (5 nmol) are incubated at 37 °C with 1 µL of purified DPP-IV corresponding to an enzymatic activity of 5mU for 10-180 minutes in 100 µL of 0.1 M triethylamine-HCl buffer, pH 7.4. Enzymatic reactions are terminated
10 by the addition of 5 µL of 10% trifluoroacetic acid, and the peptide degradation products are separated and quantified using HPLC analysis. One method for performing this analysis is: The mixtures are applied onto a Vydac C18 widepore (30 nm pores, 5 µm particles) 250 x 4.6 mm column and eluted at a flow rate of 1 ml/min with linear stepwise gradients of acetonitrile in 0.1% trifluoroacetic
15 acid (0% acetonitrile for 3 min, 0-24% acetonitrile for 17 min, 24-48% acetonitrile for 1 min) according to Siegel et al., Regul. Pept. 1999;79:93-102 and Mentlein et al. Eur. J. Biochem. 1993;214:829-35. Peptides and their degradation products may be monitored by their absorbance at 220 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of
20 their peak areas related to those of standards. The rate of hydrolysis of a peptide by dipeptidyl peptidase DPP-IV is estimated at incubation times which result in less than 10% of the peptide being hydrolysed.

In its broadest sense, the term "GLP-1 analogue" as used herein means an analogue of a molecule of the glucagon family of peptides or an analogue of the
25 family of exendins. The glucagon family of peptides are encoded by the pre-proglucagon gene and encompasses three small peptides with a high degree of homology, i.e. glucagon (1-29), GLP-1 (1-37) and GLP-2 (1-33). Exendins are peptides expressed in lizards and like GLP-1, are insulinotropic. Examples of exendins are exendin-3 and exendin-4.

The term "analogue" as used herein referring to a polypeptide means a modified peptide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been added to the peptide. Such addition or deletion of amino acid residues can take place at the N-terminal of the peptide and/or at the C-terminal of the peptide. Thus a GLP-1 analogue according to the invention is an analogue of GLP-1 (1-37) according to the invention wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been added to the peptide.

For the present purposes any amino acid substitution, deletion, and/or addition refers to the sequence of human GLP-1(7-37) which is included herein as SEQ ID NO: 1. However, the numbering of the amino acid residues in the sequence listing always starts with no. 1, whereas for the present purpose we want, following the established practice in the art, to start with amino acid residue no. 7 and assign number 7 to it. Therefore, generally, any reference herein to a position number of the GLP-1(7-37) sequence is to the sequence starting with His at position 7 and ending with Gly at position 37.

A simple system is often used to describe GLP-1 analogues: for example [Arg³⁴]GLP-1(7-37)Lys designates a GLP-1(7-37) analogue wherein the naturally occurring lysine at position 34 has been substituted with arginine and wherein a lysine has been added to the C-terminal. Another example [Arg³⁴]GLP-1(11-37) designates a GLP-1 analogue wherein the naturally occurring lysine at position 34 has been substituted with arginine and the amino acids in positions 7, 8, 9 and 10 are absent.

The expression "a position equivalent to" when used herein to characterize a modified GLP-1(7-37) sequence refers to the corresponding position in the natural GLP-1(7-37) sequence (having the sequence of SEQ ID NO: 1). Corresponding positions are easily deduced, e.g. by simple handwriting and

eyeballing. In the alternative, a standard protein or peptide alignment program may be used, such as "align" which is a Needleman-Wunsch alignment. The algorithm is described in Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48: 443-453, and the align program by Myers and W. Miller in
5 "Optimal Alignments in Linear Space" CABIOS (computer applications in the biosciences) (1988) 4:11-17. For the alignment, the default scoring matrix BLOSUM50 and the default identity matrix may be used, and the penalty for the first residue in a gap may be set at -12 and the penalties for additional residues in a gap at -2.

10

The term "derivative" as used herein in relation to a peptide means a chemically modified peptide or an analogue thereof, wherein at least one substituent has been attached to the unmodified peptide or an analogue thereof, i.e. a peptide which has been covalently modified. Typical modifications are amides, carbohydrates,
15 alkyl groups, acyl groups, esters and the like. An example of a derivative of GLP-1(7-37) is N^{ε26}-(γ-Glu(N^α-hexadecanoyl)))-[Arg³⁴, Lys²⁶])GLP-1(7-37).

All amino acids for which the optical isomer is not stated is to be understood to mean the L-isomer.

20

In embodiments of the invention a maximum of 17 amino acids in the GLP-1 analogue have been modified (substituted, deleted, added or any combination thereof) relative to human GLP-1(7-37). In embodiments of the invention a maximum of 15 amino acids in the GLP-1 analogue have been modified. In
25 embodiments of the invention a maximum of 10 amino acids in the GLP-1 analogue have been modified. In embodiments of the invention a maximum of 8 amino acids in the GLP-1 analogue have been modified. In embodiments of the invention a maximum of 7 amino acids in the GLP-1 analogue have been modified. In embodiments of the invention a maximum of 6 amino acids in the
30 GLP-1 analogue have been modified. In embodiments of the invention a maximum of 5 amino acids in the GLP-1 analogue have been modified. In embodiments of the invention a maximum of 4 amino acids in the GLP-1 analogue have been modified. In embodiments of the invention a maximum of 3 amino acids in the GLP-1 analogue have been modified. In embodiments of the

invention a maximum of 2 amino acids in the GLP-1 analogue have been modified. In embodiments of the invention 1 amino acid in the GLP-1 analogue has been modified.

In one embodiment the GLP-1 analogue is an insulinotropic agent.

- 5 In one embodiment the GLP-1 analogue is a GLP-1 agonist.

The term "GLP-1 agonist " as used herein refers to any glucagon-like peptide which fully or partially activates the human GLP-1 receptor. In a preferred embodiment, the "GLP-1 agonist" is any glucagon-like peptide that binds to a GLP-1 receptor, preferably with an affinity constant (KD) or a potency (EC₅₀) of
 10 below 1μM, e.g., below 100nM as measured by methods known in the art (see e.g., WO 98/08871) and exhibits insulinotropic activity, where insulinotropic activity may be measured *in vivo* or *in vitro* assays known to those of ordinary skill in the art. For example, the GLP-1 agonist may be administered to an animal and the insulin concentration measured over time.

- 15 In one aspect of the invention, the GLP-1 analogue to be included in the pharmaceutical compositions of the present invention is an analogue of GLP-1, wherein the analogue comprises at least one non-proteogenic peptide.

In one aspect of the invention, the GLP-1 analogue is selected from the group consisting of Aib^{8,22,35} GLP-1(7-37), Aib^{8,35} GLP-1(7-37), Aib^{8,22} GLP-1(7-37),
 20 Aib^{8,22,35} Arg^{26,34} Lys³⁸ GLP-1(7-38), Aib^{8,35} Arg^{26,34} Lys³⁸ GLP-1(7-38), Aib^{8,22} Arg^{26,34} Lys³⁸ GLP-1(7-38), Aib^{8,22,35} Arg^{26,34} Lys³⁸ GLP-1(7-38), Aib^{8,35} Arg^{26,34} Lys³⁸ GLP-1(7-38), Aib^{8,22,35} Arg²⁶ Lys³⁸ GLP-1(7-38), Aib^{8,35} Arg²⁶ Lys³⁸ GLP-1(7-38), Aib^{8,22} Arg²⁶ Lys³⁸ GLP-1(7-38), Aib^{8,22,35} Arg³⁴ Lys³⁸ GLP-1(7-38), Aib^{8,35} Arg³⁴ Lys³⁸ GLP-1(7-38), Aib^{8,22} Arg³⁴ Lys³⁸ GLP-1(7-38), Aib^{8,22,35} Ala³⁷ Lys³⁸ GLP-1(7-38),
 25 Aib^{8,35} Ala³⁷ Lys³⁸ GLP-1(7-38), Aib^{8,22} Ala³⁷ Lys³⁸ GLP-1(7-38), Aib^{8,22,35} Lys³⁷ GLP-1(7-37), Aib^{8,35} Lys³⁷ GLP-1(7-37) and Aib^{8,22} Lys³⁷ GLP-1(7-38).

In one aspect of the invention, the GLP-1 analogue is selected from the group consisting of

- [desaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1(7-37)amide,
[desaminoHis⁷,Arg³⁴]GLP-1-(7-37), [Aib⁸,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
[DesaminoHis⁷, Glu²² Arg²⁶, Arg³⁴, Phe(m-CF₃)²⁸]GLP-1-(7-37)amide,
5 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴]GLP-1-(7-37)-Lys,
[DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴]GLP-1-(7-37)-Lys,
[desaminoHis⁷,Arg²⁶,Arg³⁴,]GLP-1-(7-37)-Lys,
[DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
[DesaminoHis⁷,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
10 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37),
[DesaminoHis⁷,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37),
[DesaminoHis⁷,Glu²²,Arg²⁶,Glu³⁰,Arg³⁴,Lys³⁷]GLP-1-(7-37),
[Aib⁸,Lys²⁰,Arg²⁶,Glu³⁰,Thr(O-benzyl)³³,]GLP-1-(7-37)amide,
[Aib⁸,Glu²²,Arg²⁶,Lys³⁰]GLP-1-(7-37), [Aib⁸, Glu²², Arg²⁶,Lys³¹]GLP-1-(7-37),
15 [Aib⁸,Lys²⁰,Arg²⁶,2-Naphtylalanine²⁸, Glu³⁰,]GLP-1 (7-37)amide,
[Aib⁸, Glu²², Arg²⁶, Arg³⁴,]GLP-1-(7-37)-Lys,
[Aib⁸,Lys²⁰,Arg²⁶, 2-Naphtylalanine¹², Glu³⁰,]GLP-1-(7-37)amide,
[Aib⁸,Glu²²,Arg²⁶,Lys³¹,Arg³⁴]GLP-1-(7-37),
[Aib⁸,Arg³⁴]GLP-1-(7-37),
20 [Aib⁸,Arg³⁴]GLP-1-(7-37)-amide,
[Aib⁸,Lys¹⁸,Arg²⁶,Arg³⁴]GLP-1(7-37),
[Aib⁸,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
[Aib⁸, Lys²⁶] GLP-1 (7-37)amide,
[Aib⁸,Arg³⁴]GLP-1-(7-34),
25 [Aib⁸,Arg³⁴]GLP-1-(7-35),
[Aib⁸,Lys³³,Arg³⁴]GLP-1-(7-34),
[Aib⁸,Arg³⁴]GLP-1-(7-36)amide,
[Aib⁸,Lys²⁶,Arg³⁴]GLP-1-(7-36)amide,
[Aib⁸,Glu²²,Arg²⁶,Arg³⁴]GLP-1-(7-37)Lys,
30 [Aib⁸,Lys²⁰,Glu²²,Arg²⁶,Glu³⁰,Pro³⁷]GLP-1-(7-37)amide,
[Aib⁸,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
[DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
[DesaminoHis⁷,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,

Aib⁸,Glu²²,Arg²⁶,Glu³⁰,Pro³⁷]GLP-1-(7-37)Lys,
[Aib⁸,Glu²²,Arg²⁶,Glu³⁰,Pro³⁷]GLP-1-((7-37)Lys,
[Aib⁸,Arg²⁶,Arg³⁴]GLP-1-(7-37).

- 5 In yet another embodiment, the GLP-1 analogue to be included in the pharmaceutical compositions of the present invention is an analogue of GLP-2, wherein the analogue comprises at least one non-proteogenic peptide.

In yet another embodiment the GLP-1 analogue is an analogue of exendin-4 or exendin-3, wherein the analogue comprises at least one non-proteogenic
10 peptide. Examples of exendins as well as analogues thereof are disclosed in WO 97/46584, US 5424286 and WO 01/04156. US 5424286 describe a method for stimulating insulin release with an exendin peptide. The exendin peptides disclosed include HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGX (SEQ ID NO. 12), wherein X-P or Y, and wherein exendin-3 is
15 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO. 13) and exendin-4 (1-39) is HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO. 2). WO 97/46584 describes truncated versions of exendin peptide(s). The disclosed peptides increase secretion and biosynthesis of insulin, but reduce those of glucagon. WO 01/04156 describes exendin-4 analogues and derivatives
20 as well as the preparation of these molecules.

- The term "exendin-4 peptide" as used herein means exendin-4(1-39) (SEQ ID NO. 2), an exendin-4(1-39) analogue, an exendin-4(1-39) derivative or a derivative of an exendin-4(1-39) analogue, insulinotropic fragments thereof, insulinotropic analogs thereof and insulinotropic derivatives thereof.
- 25 Insulinotropic fragments of exendin-4 are insulinotropic agents for which the entire sequence can be found in the sequence of exendin-4 (SEQ ID NO. 2) and where at least one terminal amino acid has been deleted. Examples of insulinotropic fragments of exendin-4(1-39) are exendin-4(1-38) and exendin-4(1-31).
- 30 The insulinotropic property of a compound may be determined by *in vivo* or *in vitro* assays well known in the art. For instance, the compound may be

administered to an animal and monitoring the insulin concentration over time. Insulinotropic analogs of exendin-4(1-39) refer to the respective molecules wherein one or more of the amino acids residues have been exchanged with other amino acid residues and/or from which one or more amino acid residues have been deleted and/or from which one or more amino acid residues have been added with the proviso that said analogue either is insulinotropic or is a prodrug of an insulinotropic compound. An example of an insulinotropic analog of exendin-4(1-39) is Ser²Asp³-exendin-4(1-39) wherein the amino acid residues in position 2 and 3 have been replaced with serine and aspartic acid, respectively (this particular analog also being known in the art as exendin-3). Insulinotropic derivatives of exendin-4(1-39) and analogs thereof are what the person skilled in the art considers to be derivatives of these peptides, i.e., having at least one substituent which is not present in the parent peptide molecule with the proviso that said derivative either is insulinotropic or is a prodrug of an insulinotropic compound. Examples of substituents are amides, carbohydrates, alkyl groups, esters and lipophilic substituents. An example of an insulinotropic derivatives of exendin-4(1-39) and analogs thereof is Tyr³¹-exendin-4(1-31)-amide.

The term "stable exendin-4 compound" as used herein means a chemically modified exendin-4(1-39), i.e., an acylated exendin-3 or acylated exendin-4 analogue which exhibits an *in vivo* plasma elimination half-life of at least 10 hours in man, as determined by conventional methods.

All amino acids for which the optical isomer is not stated is to be understood to mean the L-isomer.

The term "insulinotropic agent" as used herein means a compound which is an agonist of the human GLP-1 receptor, i.e. a compound which stimulates the formation of cAMP in a suitable medium containing the human GLP-1 receptor (one such medium disclosed below). The potency of an insulinotropic agent is determined by calculating the EC₅₀ value from the dose-response curve as described below.

Baby hamster kidney (BHK) cells expressing the cloned human GLP-1 receptor (BHK- 467-12A) were grown in DMEM media with the addition of 100 IU/mL penicillin, 100 µg/mL streptomycin, 5% fetal calf serum and 0.5 mg/mL Geneticin G-418 (Life Technologies). The cells were washed twice in phosphate buffered saline and harvested with Versene. Plasma membranes were prepared from the cells by homogenisation with an Ultraturrax in buffer 1 (20 mM HEPES-Na, 10 mM EDTA, pH 7.4). The homogenate was centrifuged at 48,000 x g for 15 min at 4°C. The pellet was suspended by homogenization in buffer 2 (20 mM HEPES-Na, 0.1 mM EDTA, pH 7.4), then centrifuged at 48,000 x g for 15 min at 4°C. The washing procedure was repeated one more time. The final pellet was suspended in buffer 2 and used immediately for assays or stored at -80°C.

The functional receptor assay was carried out by measuring cyclic AMP (cAMP) as a response to stimulation by the insulinotropic agent. cAMP formed was quantified by the AlphaScreen™ cAMP Kit (Perkin Elmer Life Sciences). Incubations were carried out in half-area 96-well microtiter plates in a total volume of 50 µL buffer 3 (50 mM Tris-HCl, 5 mM HEPES, 10 mM MgCl₂, pH 7.4) and with the following additions: 1 mM ATP, 1 µM GTP, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.01 % Tween-20, 0.1% BSA, 6 µg membrane preparation, 15 µg/mL acceptor beads, 20µg/mL donor beads preincubated with 6 nM biotinyl-cAMP. Compounds to be tested for agonist activity were dissolved and diluted in buffer 3. GTP was freshly prepared for each experiment. The plate was incubated in the dark with slow agitation for three hours at room temperature followed by counting in the Fusion™ instrument (Perkin Elmer Life Sciences). Concentration-response curves were plotted for the individual compounds and EC₅₀ values estimated using a four-parameter logistic model with Prism v. 4.0 (GraphPad, Carlsbad, CA).

The term "semi-recombinant" as used herein refers to a method comprising the steps of preparing a first peptide fragment such as a first fragment of a GLP-1 analogue by a recombinant process, i.e. from a culture of host cells, and subsequently coupling a second fragment of a peptide to the first fragment of the peptide, wherein the second fragment is prepared chemically, i.e. in solution or on

a resin using solid phase peptide chemistry. The coupling of the fragments may be performed either chemically or enzymatically.

The term "separating the expressed precursor molecule" as used herein means any kind of separation, including isolation of the recombinantly produced
5 compound and also includes disintegrating or permeabilising a host cell.

Accordingly, the present invention relates to a method for making a GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

- 10 (i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue or derivative under suitable conditions for expression of said precursor molecule,
- (ii) separating the expressed precursor molecule from the culture broth,
- (iii) coupling an N-terminal amino acid extension comprising one or more non-
15 proteogenic amino acids to the expressed precursor molecule,
- (iv) isolating the resulting GLP-1 analogue or derivative by suitable means, as known in the art.

In the present context, the term "precursor molecule of the GLP-1 analogue", is
20 to be understood as a peptide derived from GLP-1, GLP-2, Exendin-3 or Exendin-4 peptides, i.e., a GLP-1 analogue sequence, before addition of an N-terminal amino acid extension. Examples include, but are not limited to human GLP-1 (11-37) or an analogue thereof, human GLP-1 (9-37) or an analogue thereof and human GLP-1 (8-37) or an analogue thereof.

25 Accordingly, in one aspect the precursor molecule of the GLP-1 analogue according to the invention, comprises a GLP-1 peptide derived from the GLP-1 (7-37) sequence as shown in SEQ ID NO:1.

Exendin-4 is a 39 amino acid residue peptide isolated from the venom of Gila monster lizards (*Heloderma suspectum* and *Heloderma horridum*). This peptide
30 shares 52% homology with GLP-1 (7-37) in the overlapping region. Exendin-4 is

a potent GLP-1 receptor agonist and has also been shown to stimulate insulin release and ensuing lowering of the blood glucose level when injected into dogs.

Thus, due to the 52% homology with GLP-1 (7-37) in the overlapping region, the precursor molecule of the GLP-1 analogue according to the invention, may in certain embodiments be derived from an exendin-4 peptide as shown in SEQ ID NO:2.

Accordingly, the precursor molecules of the GLP-1 analogue may in a further aspect comprise an amino acid sequence of the general formula:

Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-
10 Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-
Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ (SEQ ID NO:3)

wherein

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Lys or Arg;

15 Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys or Arg;

Xaa₂₅ is Ala or Val;

20 Xaa₂₆ is Lys, Glu or Arg;

Xaa₂₇ is Glu or Leu;

Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₃ is Val, Lys or Arg;

Xaa₃₄ is Lys, Glu, Asn, His or Arg;

25 Xaa₃₅ is Gly;

Xaa₃₆ is Arg, Gly or Lys;

Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;

Xaa₃₈ is Lys, Ser, or is absent.

Xaa₃₉ is Ser, Lys, or is absent;

30 Xaa₄₀ is Gly, or is absent;

Xaa₄₁ is Ala, or is absent;

Xaa₄₂ is Pro, or is absent;

Xaa₄₃ is Pro, or is absent;

Xaa₄₄ is Pro, or is absent;

5 Xaa₄₅ is Ser, or is absent;

provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent then each amino acid residue downstream is also absent.

In a further aspect of the invention, the precursor molecule of the GLP-1 analogue is selected from the list of precursor molecules comprising the amino acid sequence of the general formula:

Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-
Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-
Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ (SEQ ID NO:4)

wherein

15 Xaa₉ is Glu or Asp

Xaa₁₀ is Gly or Ala

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Lys or Arg;

Xaa₁₉ is Tyr or Gln;

20 Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys or Arg;

Xaa₂₅ is Ala or Val;

Xaa₂₆ is Lys, Glu or Arg;

25 Xaa₂₇ is Glu or Leu;

Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₃ is Val, Lys or Arg;

Xaa₃₄ is Lys, Glu, Asn, His or Arg;

Xaa₃₅ is Gly;

30 Xaa₃₆ is Arg, Gly or Lys;

Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;

Xaa₃₈ is Lys, Ser, or is absent.

Xaa₃₉ is Ser, Lys, or is absent;

Xaa₄₀ is Gly, or is absent;

Xaa₄₁ is Ala, or is absent;

5 Xaa₄₂ is Pro, or is absent;

Xaa₄₃ is Pro, or is absent;

Xaa₄₄ is Pro, or is absent;

Xaa₄₅ is Ser, or is absent;

provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent

10 then each amino acid residue downstream is also absent.

In a further aspect of the invention, the precursor molecule of the GLP-1 analogue is selected from the precursor molecules comprising an amino acid sequence of the general formula:

15 Xaa₈- Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-
Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-
Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ (SEQ ID NO:5)

wherein

Xaa₈ is Ala, Gly, Val, Leu, Ile or Lys;

Xaa₉ is Glu or Asp;

20 Xaa₁₀ is Gly or Ala;

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Lys or Arg;

Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

25 Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys or Arg;

Xaa₂₅ is Ala or Val;

Xaa₂₆ is Lys, Glu or Arg;

Xaa₂₇ is Glu or Leu;

30 Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₃ is Val, Lys or Arg;

Xaa₃₄ is Lys, Glu, Asn, His or Arg;

Xaa₃₅ is Gly;

Xaa₃₆ is Arg, Gly or Lys;

Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;

5 Xaa₃₈ is Lys, Ser, or is absent;

Xaa₃₉ is Ser, Lys, or is absent;

Xaa₄₀ is Gly, or is absent;

Xaa₄₁ is Ala, or is absent;

Xaa₄₂ is Pro, or is absent;

10 Xaa₄₃ is Pro, or is absent;

Xaa₄₄ is Pro, or is absent;

Xaa₄₅ is Ser, or is absent;

provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent then each amino acid residue downstream is also absent.

15 The GLP-1 analogue precursor molecules of the present invention may be prepared by means of recombinant DNA technology using general methods and principles known to the person skilled in the art, by culturing a suitable host cell comprising a nucleotide sequence encoding a precursor molecule of the GLP-1 analogue under suitable conditions for expression of the precursor molecule.

20 The nucleic acid sequence encoding the precursor molecule of the GLP-1 analogue may be prepared synthetically by established standard methods well known in the art, e.g. by synthesizing oligonucleotides in an automatic DNA synthesizer, and subsequently purify, anneal, ligate and clone the nucleic acid sequences into suitable vectors.

25 The cloning of the nucleic acid sequences encoding the precursor molecule of the GLP-1 analogue can be effected, e.g., by using the well known polymerase chain reaction (PCR).

The nucleic acid sequence encoding the precursor molecule of the GLP-1 analogue is inserted into a recombinant expression vector which may be any
30 vector which may conveniently be subjected to recombinant DNA procedures.

The choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid. Alternatively, the
5 vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

For extracellular products the proteinaceous components of the supernatant are isolated by filtration, column chromatography or precipitation, e. g.

10 microfiltration, ultrafiltration, isoelectric precipitation, purification by a variety of chromatographic procedures, e. g. ion exchange chromatography, hydrophobic interaction chromatography, gel filtration chromatography, affinity
chromatography, or the like, dependent on the type of polypeptide in question.

For intracellular or periplasmic products the cells isolated from the culture
15 medium are disintegrated or permeabilised and extracted to recover the product polypeptide or precursor thereof.

The DNA sequence encoding the precursor molecule of the GLP-1 analogue may suitably be of genomic or cDNA origin, for instance obtained by preparing a
20 genomic or cDNA library and screening for DNA sequences coding for all or part of the peptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning : A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989). The DNA sequence encoding the polypeptide
25 may also be prepared synthetically by established standard methods, e. g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859-1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801-805. The DNA sequence may also be prepared by
polymerase chain reaction using specific primers, for instance as described in US
30 4,683, 202 or Saiki et al., Science 239 (1988), 487-491.

The DNA sequence encoding the precursor molecule of the GLP-1 analogue may

be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i. e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome (s) into which it has been integrated.

- 10 The vector is preferably an expression vector in which the DNA sequence encoding the precursor molecule of the GLP-1 analogue is operably linked to additional segments required for transcription of the DNA, such as a promoter. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra.
- 20 The DNA sequence encoding the precursor molecule of the GLP-1 analogue may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences. The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.

- The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e. g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate. For large scale manufacture the selectable marker preferably is not antibiotic resistance, e. g. antibiotic resistance genes in the vector are preferably excised when the vector is used for large scale manufacture. Methods for eliminating antibiotic resistance genes from vectors

are known in the art, see e.g. US 6,358, 705 which is incorporated herein by reference.

To direct precursor molecule of the GLP-1 analogue of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide. The secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.

The procedures used to ligate the DNA sequences coding for the precursor molecule of the GLP-1 analogue, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., supra).

The host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the precursor molecule of the GLP-1 analogue and includes, but is not limited to, mammalian host cells, avian host cells, insect host cells, plant host cells, bacterial host cells, fungal host cells and yeast host cells. Examples of suitable host cells well known and used in the art include, but are not limited to *Saccharomyces cerevisiae*, *Pichia pastoris* and other yeasts, *E. coli*, *Bacillus subtilis*, and *Pseudomonas fluorescens* or mammalian BHK or CHO cell lines.

The methods of introducing exogenous nucleic acid into the hosts are well known in the art, and will vary with the host cell used. The host cell, when cultured under appropriate conditions, synthesizes a GLP-1 precursor molecule which can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted).

In one embodiment, GLP-1 precursor molecules are produced in yeast cells. Yeast expression hosts are well known in the art, and include but are not limited to *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guillermondii*, *Pichia methanolica* and *Pichia pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*.

In a one embodiment, GLP-1 precursor molecules are produced in bacterial systems. Bacterial expression hosts are well known in the art, and include but are not limited to *E. coli*, *Bacillus subtilis*, *Pseudomonas fluorescens*, *Lactococcus lactis*, *Streptococcus cremoris*, and *Streptococcus lividans*.

In one embodiment, GLP-1 precursor molecules are expressed in filamentous fungi. Filamentous fungi hosts are well known in the art, and include but are not limited to *Neurospora*, *Penicillium*, *Tolypocladium*, and *Aspergillus* hosts such as *Aspergillus nidulans*, *Aspergillus oryzae* and *Aspergillus niger*.

In one embodiment, GLP-1 precursor molecules are produced in insect cells. Expression systems have been developed for *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Spodoptera frugiperda*, and *Trichoplusia ni*. Each of these cell lines is known by and available to those skilled in the art of protein expression.

In one embodiment, GLP-1 precursor molecules are produced in other higher eukaryotic cells. These include but are not limited to avian cells and plant cells such as *Chlamydomonas reinhardtii*.

In one embodiment, GLP-1 precursor molecules are produced in mammalian host cell lines. Examples of these include, but are not limited to Baby hamster kidney (BHK), Chinese hamster ovary (CHO) and COS cells. More specific examples include, but are not limited to monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293); human liver cells (Hep G2, HB 8065).

The appropriate host cell is selected by the person the skill in the art.

The medium used to culture the host cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e. g. in catalogues of the American Type Culture Collection).

The precursor molecule of the GLP-1 analogue produced by the cells may then be separated from the culture broth or culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration.

As mentioned above, it is an aspect of the present invention to couple an N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the expressed GLP-1 analogue precursor molecule, in order to render the compound more resistant to the plasma peptidase dipeptidyl peptidase-4 (DPP-IV).

Such non-proteogenic amino acids may be selected from γ -carboxyglutamate, ornithine, phosphoserine, D-amino acids such as D-alanine and D-glutamine, D-alanine and D-leucine, Aib (α -aminoisobutyric acid), Abu (α -aminobutyric acid), Tle (tert-butylglycine), 3-aminomethyl benzoic acid, anthranilic acid, des-amino-Histidine, β -alanine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N α -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine, 4-pyridylalanine, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, (1-aminocyclooctyl) carboxylic acid, α -methyl prolin, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine. The desamino-histidine, although not containing an amino group, is thus herein referred to as a non-proteogenic amino acid, for ease in classification and nomenclature.

In one aspect of the invention, the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 1 amino acid, 2 amino acids, 3 amino acids or 4 amino acids.

5 In one aspect of the invention, the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 1 amino acid, 2 amino acids or 4 amino acids.

In one aspect of the invention, the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 1 amino acid or 2 amino acids.

10 In one aspect of the invention, the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 2 amino acids.

In one aspect of the invention, the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 1 amino acid.

15 It is contemplated that not all of the amino acids of the N-terminal amino acid extension necessarily are non-proteogenic amino acids. Hence, in certain aspects the N-terminal amino acid extension comprises 1, 2, 3 or 4 non-proteogenic amino acids.

In one aspect of the invention the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

20 $Xaa_7-Xaa_8-Xaa_9-Xaa_{10}$

wherein

Xaa_7 is selected from L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N^α -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and
25 4-pyridylalanine, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine;

Xaa₈ is selected from Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid and alpha-methyl proline

- 5 Xaa₉ is selected from Glu, Asp, γ,γ-dimethyl Glu, β,β-dimethyl Glu and β,β-dimethyl Asp, and

Xaa₁₀ is selected from Gly, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, and (1-aminocyclooctyl) carboxylic acid.

10

The free carboxylic acid of the sequence Xaa₇-Xaa₈- Xaa₉-Xaa₁₀ may efficiently be prepared in a solution or on a resin such as 2-chlorotriethylchloride resin e.g. via an Fmoc based strategy using adequately protected building blocks using appropriate reaction conditions described in references (Organic Synthesis on solid Phase, Florencio Zaragoza Dörwald, Wiley-VCH Verlag GmbH, D-69469 Weinheim, 2000), (Novabiochem Catalog, Merck Biosciences 2006/2007) and (Fmoc Solid Phase Peptide Synthesis, Edited by W.C. Chan and P.D. White, Oxford University Press, 2000, ISBN 0-19-963724-5). The amino acids in the sequence can be protected or unprotected. The N-terminal extension peptide of sequence Xaa₇-Xaa₈-Xaa₉-Xaa₁₀ may be activated to an activated acylating agent. The term "activated" acylating agent means an acylating agent which has been activated using general techniques as e.g. described in "Amide bond formation and peptide coupling" [Tetrahedron 61(46), 10827-10852 (2005)]. Examples of activated esters include, but are not limited to acid chloride, acid bromides, acid fluorides, symmetrical anhydride, mixed anhydride, carboxylic acids activated using common carbodiimides such as but not limited to diisopropylcarbodiimide (DIPCDI), *N,N'*-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDC). Furthermore, included, but not limited to, are carboxylic acids using the aforementioned carbodiimides and an additive such as but not limited to *N*-hydroxybenzotriazol (HOBt), 1-Hydroxy-7-azabenzotriazole, 6-chloro-*N*-hydroxybenzotriazol (HOAt),

15

20

25

30


3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (DhbtOH). Also included, but not limited to, are carboxylic acids activated with an uronium salt or a phosphonium salt, such as but not limited to O-Benzotriazole-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HBTU), O-(Benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU), 2-(6-Chloro-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), (2-(6-Chloro-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate) (TCTU), 2-(1*H*-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 1-benzotriazolyoxytris-

10 (dimethylamino)phosphonium hexafluorophosphate (BOP) benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PYBOP). Other activated esters include, but are not limited to esters of N-hydroxysuccinimid (NHS ester), pentafluorophenol ester (PfP-ester), 2,4-dinitrophenyl ester, 4-nitrophenyl ester, 3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (HODhbt) and

15 Carbonyldiimidazole (CDI), *N*-ethyl-5-phenylisoxazolium-3'-sulfonate (NEPIS), preferably a N-hydroxysuccinimide ester or a HOBt ester or a derivative hereof using reaction conditions described in references (Organic Synthesis on solid Phase, Florencio Zaragoza Dörwald, Wiley-VCH Verlag GmbH, D-69469 Weinheim, 2000), (Novabiochem Catalog, Merck Biosciences 2006/2007) and

20 (Fmoc Solid Phase Peptide Synthesis, Edited by W.C. Chan and P.D. White, Oxford University Press, 2000, ISBN 0-19-963724-5).


One example of an N-terminal extension peptide having the general formula Xaa₇-Xaa₈- Xaa₉-Xaa₁₀ is;



25 wherein R1 and R2 are individually chosen protecting groups such as but not limited to: Carbamates including but not limited to 9*H*-fluoren-9-ylmethoxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc) and Benzylcarbamate (Cbz); Amides including but not limited to benzamide; imides including but not

limited to N-Phthalimide; and alkyls including but not limited to 1-Adamantyl (1-Adoc) and triphenylmethyl (Trt). In a preferred embodiment R1 is selected from the group consisting of 9*H*-fluoren-9-ylmethoxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc) and benzylcarbarmate (Cbz), and R2 is selected from the group consisting of tert-butoxycarbonyl (Boc) and triphenylmethyl (Trt). R3 is an individually chosen protecting group such as but not limited to: Esters including but not limited to methyl, ethyl, tert-butyl, benzyl and 9*H*-fluoren-9-ylmethyl (Fm). In a preferred embodiment R3 is tert-butyl or benzyl.

An example of an N-terminal extension peptide of the sequence Xaa₇-Xaa₈-Xaa₉-Xaa₁₀ which is activated as the corresponding N-hydroxysuccinimide ester is;



wherein R1, R2, and R3 are individually chosen protecting groups such as described above.

In a further aspect of the invention the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

Xaa₇-Xaa₈


wherein

Xaa₇ is selected from L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N^α-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine; 1-methyl histidine, 3-methyl histidine, 4,5,6,7-tetrahydro-1*H*-imidazo[4,5-*C*]pyridine-6-carboxylic acid β-(1,2,4-triazol-1-yl)-alanine; and

Xaa₈ is selected from Gly, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid and alpha-methyl proline


- 5 The free carboxylic acid of the sequence Xaa₇-Xaa₈ may efficiently be prepared on a resin such as 2-chlorotritylchloride resin e.g. via an Fmoc based strategy using adequately protected building blocks using appropriate reaction conditions as described above or alternatively it may be prepared in solution. The amino acids in the sequence can be protected or unprotected.
- 10 The N-terminal extension peptide of sequence Xaa₇-Xaa₈ may be activated to activated acylating agents as described above.

An example of a N-terminal extension peptide with the formula Xaa₇-Xaa₈ is:



- 15 wherein R1 and R2 are individually chosen protecting groups as described above.

An example of an N-terminal extension peptide with the sequence Xaa₇-Xaa₈ which is activated as the corresponding N-hydroxysuccinimide ester is;



- 20 wherein R1 and R2 are individually chosen protecting groups as described above.

In a yet further aspect of the invention, the N-terminal amino acid extension comprising one non-proteogenic amino acid has the general formula


Xaa₇

wherein

- 5 Xaa₇ is selected from D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N^α-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine; 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β-(1,2,4-triazol-1-yl)-alanine.
- 10 The free carboxylic acid of Xaa₇ may efficiently be prepared on a resin such as 2-chlorotriylchloride resin using adequately protected building blocks using appropriate reaction conditions described as described above or alternatively may be prepared in a solution. The amino acid can be protected or unprotected.


- 15 The amino acid in the N-terminal extension Xaa₇ may be activated to an activated acylating agent as described above.

An example of an amino acid of the formula Xaa₇ is;



wherein R2 is a protecting group as described above or hydrogen.

- 20 An example of an amino acid of the formula Xaa₇ which is activated as the corresponding N-hydroxysuccinimide ester is:



In a further aspect of the invention, the GLP-1 analogue produced according to the invention, is a GLP-1 analogue wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula Xaa₇-Xaa₈- Xaa₉- Xaa₁₀ as defined above;

5 and the precursor molecule of said GLP-1 analogue has the general formula

Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ as defined above.

10 In a further aspect of the invention, the GLP-1 analogue produced according to the invention, is a GLP-1 analogue wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

Xaa₇-Xaa₈ as defined above;

and the precursor molecule of said GLP-1 analogue has the general formula

15 Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ as defined above.

20 In a yet further aspect of the invention, the GLP-1 analogue produced according to the invention, is a GLP-1 analogue wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

Xaa₇ as defined above;

and the precursor molecule of said GLP-1 analogue has the general formula

Xaa₈- Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-
Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-
Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ as defined above.

Coupling of additional amino acid analogues on an unprotected polypeptide
5 fragment such as the GLP-1 analogue precursor molecule may not be a trivial
task, due to the large number of possible side reactions that can take place
under the reaction conditions used. An electrophilic reagent like for example an
active ester such as an N-hydroxysuccinimide ester will in general react with
nucleophiles present in a polypeptide. Such nucleophiles can be thiols, amines,
10 imidazoles, phenolic hydroxy groups, alcohols, and guanidines. The rate of
acylation on the functional groups will depend on the inherent reactivity of
individual groups but also on the primary, secondary, tertiary and even
quaternary structure of the polypeptide. Therefore it will often be difficult to
forecast the relative reactivity of different amino acid moieties in a polypeptide.
15 In practice reactions on an unprotected polypeptide give rise to mixtures of
products. The relative reactivity of the individual groups in a polypeptide can
however in some cases partly be controlled by the conditions under which the
reaction is performed. Hence, a change in pH in a reaction mixture can lead to
altered reactivity of some groups. Likewise, a change in the solvent from a non-
20 protic to a protic one can result in altered reactivity of some groups.

In the method according to the invention, the coupling of the N-terminal amino
acid extension comprising one or more non-proteogenic amino acids to the GLP-
1 precursor molecule, may in certain useful embodiments take place in a
solvent, including an organic polar solvent selected from 1-methyl-pyrrolidin-2-
25 one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-dimethylformamide and
N-methyl-formamide.

In other useful embodiments, the coupling of the N-terminal amino acid
extension may take place in an aqueous solvent mixture, such as an aqueous
solvent mixture that may comprise an organic polar solvent, such as a solvent
30 selected from 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran,
dimethylsulfoxide, *N,N*-dimethylformamide and *N*-methyl-formamide.

Furthermore, it has been found that the coupling of the N-terminal amino acid extension according to the invention, may in useful embodiments take place in an aqueous solvent mixture, wherein the pH in the reaction mixture is between 6 and 12, such as between 7 and 10. In further embodiments the pH in the
5 reaction mixture is in the range of 7-8, 8-9, 9-10 or 10-12.

As previously mentioned, the amino acids in the N-terminal amino acid extension comprising one or more non-proteogenic amino acids may comprise one or more protection groups. Hence, it is contemplated that the method according to the invention may further comprise one or more steps of removing
10 one or more of these protection groups from the N-terminal amino acid extension comprising one or more non-proteogenic amino acids. Such deprotection steps are well described in the literature.

The method according to the invention may include a further step of acylating the epsilon-amino-group of at least one lysine residue in the expressed
15 precursor molecule or the GLP-1 analogue obtained from coupling the N-terminal extension molecule to the expressed precursor molecule, with an acylating agent.

In certain embodiments it may be advantageous to conduct this step before the coupling of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the GLP-1 analogue precursor molecule. Hence, the
20 GLP-1 analogue precursor molecule used in the method according to the invention may in certain embodiments be acylated with an acylating agent, optionally activated, on e.g. an epsilon-amino-group of a lysine residue.

Thus, in one aspect the present invention is related to a method for making a
25 GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

(i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue under suitable conditions for expression of said precursor molecule,

(ii) separating the expressed precursor molecule from the culture broth,

(iii) optionally acylating the epsilon-amino-group of at least one lysine residue in the expressed precursor molecule with an acylating agent, which is optionally activated, to obtain a precursor molecule derivative, and optionally isolating said precursor molecule derivative,

(iv) coupling an N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the expressed precursor molecule or precursor molecule derivative,

(v) isolating the resulting GLP-1 analogue or derivative by suitable means.

10 The method according to the invention may optionally further include a step of selectively protecting the epsilon-amino-group of at least one lysine residue with an amine protecting agent as described above.

In certain embodiments it may be advantageous to conduct this protection step prior to the coupling of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the GLP-1 analogue precursor molecule. Hence, the resulting lysine-protected GLP-1 analogue precursor molecule derivative used in the method according to said embodiment of the invention may be coupled to the N-terminal amino acid extension comprising one or more non-proteogenic amino acids. After said coupling of the N-terminal amino acid extension to the lysine-protected GLP-1 analogue precursor molecule, the protection group(s) on the epsilon amine groups of any lysine(s) may be removed using conventional techniques and the resulting epsilon-amino-group of a lysine may optionally be acylated with an acylating agent, optionally activated.

Thus, in one aspect the present invention is related to a method for making a GLP-1 analogue comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

(i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said insulinotropic peptide under suitable conditions for expression of said precursor molecule,

(ii) separating the expressed precursor molecule from the culture broth,

5 (iii) protecting the epsilon-amino-group of at least one lysine residue in the expressed precursor molecule with a protecting agent to obtain a protected precursor molecule, and optionally isolating said protected precursor molecule,

(iv) coupling an N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the protected precursor molecule to obtain a
10 protected GLP-1 analogue and optionally isolating said protected GLP-1 analogue,

(v) deprotection of epsilon amino protection groups, and optionally isolating the resulting GLP-1 analogue,

(vi) optionally acylating the epsilon-amino-group of at least one lysine residue in
15 the GLP-1 analogue with an acylating agent, which is optionally activated, to obtain a precursor molecule derivative,

(vii) isolating the resulting GLP-1 analogue or derivative by suitable means, as known in the art.


In one aspect of the invention, the acylating agent used in the acylation of the
20 epsilon-amino-group of a lysine residue is a carboxylic acid analogue of the general formula:

A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH

wherein one terminal free carboxylic acid, such as the -OH group of A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH, optionally is activated and wherein any other
25 contained free carboxylic acid(s) optionally are protected with appropriate protecting group(s) e.g. selected from but not limited to tert-butyl, benzyl or allyl and


wherein

A is selected from the group consisting of;




- 5 wherein n is selected from the group consisting of 14, 15, 16 17, 18 and 19, p is selected from the group consisting of 10, 11, 12, 13 and 14, and d is selected from the group consisting of 0, 1, 2, 3, 4 and 5, and m is selected from the group consisting of 11, 12, 13, 14, 15, 16, 17, k is selected from the group consisting of 0, 1, 2, 3, 4, 5, 11 and 27, and m is selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6, and R1 is selected from the group of 9H-fluoren-9-ylmethoxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc), Benzylcarbamate (Cbz)-
- 10

B is selected from the group consisting of









- 15 wherein x is selected from the group consisting of 0, 1, 2, 3 and 4, and y is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12,

C is selected from the group consisting of



wherein b and e are each independently selected from the group consisting of 0, 1 and 2, and c and f are each independently selected from the group consisting of 0, 1 and 2 with the proviso that b is 1 or 2 when c is 0, or b is 0 when c is 1 or 2, and e is 1 or 2 when f is 0, or e is 0 when f is 1 or 2, and D is selected from the group consisting of



, and

and wherein k is selected from the group consisting of 0, 1, 2, 3, 4, 5, 11 and 27, and m is selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6.


In one aspect of the invention the fragments A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH used in the acylation of the ϵ -N of a lysine moiety are carboxylic acid
5 derivatives that are activated to activated acylating agents as described above.

In one aspect of the invention a free functional chemical group, such as a contained carboxylic acid in fragment A or C of the fragments A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH is protected with an appropriate protecting group selected from but not limited to tert-butyl, benzyl or allyl.


10 When used herein the term "contained" in connection with a peptide and/or an acylating agent about a functional chemical group, such as a carboxylic acid, shall mean a functional chemical group present in the peptide or acylating agent.

The carboxylic acid derivatives may efficiently be prepared on a resin such as 2-chlorotritylchloride resin via an Fmoc based strategy using adequately protected
15 building blocks using the reaction conditions described in (Fmoc Solid Phase Peptide Synthesis, Edited by W.C. Chan and P.D. White, Oxford University Press, 2000, ISBN 0-19-963724-5).






An example of a fragment A-B-C-D-OH is:




20 The corresponding activated analogue could be the N-hydroxysuccinimide ester;






Examples of fragments A-B-C-D-:





5







5








Examples of fragments A-C-D-:







10






5





5 Examples of fragments A-B-C-:



- 10 In all the specific mentioned fragments A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH any contained free carboxylic acid(s), may optionally be protected with an appropriate protecting group selected from but not limited to tert-butyl, benzyl or allyl.


- In all the specific mentioned fragments A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH the chiral centers whether specified or not may be either the R or S enantiomer independent of other chiral centers in the same fragment.
- 15

In one embodiment, when one or more chiral centers are present, the fragments may be in the form of a mixture of enantiomers.

In another embodiment, when one or more chiral centers are present, the fragments may be in the form of a pure enantiomer, wherein each of the chiral
5 centers are either R or S.

In another embodiment, the chirality is as depicted in the specifically mentioned fragments of the present invention.

In one aspect of the invention the epsilon amine protection group of a lysine amino acid residue may be selected from, but is not limited to, the following
10 examples:



In the method according to the invention, the acylation step may in certain useful embodiments take place in a solvent, including an organic polar solvent selected from 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran,
15 dimethylsulfoxide, *N,N*-dimethylformamide and *N*-methyl-formamide.

In a further embodiment, the acylation step may take place in an aqueous solvent mixture, such as an aqueous solvent mixture comprising an organic polar solvent. Such organic polar solvent may advantageously be selected from 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-
20 dimethylformamide and *N*-methyl-formamide.

In a further embodiment, the acylation step may take place in aqueous solution.

The amount of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide and *N,N*-dimethylformamide or *N*-methyl-formamide may in certain embodiments be such that the amount of said solvent is less than 80% (v/v), such as less than 50% (v/v). In other aspects the amount of 1-methyl-
5 pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-dimethylformamide or *N*-methyl-formamide is in the range of about 40-80% (v/v), including the range of 40-45, 45-50, 50-60, 60-70 and 70-80% (v/v). It is furthermore contemplated that the acylating agent may be added to the reaction mixture as a solid.

- 10 The pH value of the aqueous solvent reaction mixture wherein the acylation step takes place, is in useful embodiments between 9 and 13, such as between 10 and 12, including between 10.5 and 11.5. In further embodiments the pH in the reaction mixture is in the range of 9-10, 10-11, 11-12 or 12-13.

- 15 The acylating agent used in accordance with the invention, may comprise one or more protection groups. Hence, it is contemplated that the method according to the invention may further comprise one or more steps of removing one or more of these protection groups from the acylating agent once it has been coupled to the GLP-1 analogue precursor molecule. Such deprotection steps are well described in the literature.

- 20 Efficient heterologous protein expression in host cells, often require that the protein is expressed in the form of a pro-peptide, i.e. a polypeptide having a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence). However, this leader sequence is normally not wanted in the desired polypeptide, and therefore the method according to the invention may in
25 certain aspects include a further step of removing N-terminal and/or C-terminal pro-peptide extensions from the GLP-1 analogue precursor molecule.

The method according to the invention comprises a step of isolating the resulting GLP-1 analogue or derivative by suitable means, e.g. standard purification methods known in the art.

It is also within the scope of the invention that the GLP-1 analogues or derivatives resulting from the method according to the invention in certain embodiments may be derivatized with an albumin binding moiety or be pegylated.

- 5 The leader sequences of the present invention may be in the optimized form as listed in figure 4.

The term "albumin binding moiety" as used herein means a residue which binds non-covalently to human serum albumin. The albumin binding residue attached to the therapeutic polypeptide typically has an affinity below 10 μ M to human
10 serum albumin and preferably below 1 μ M. A range of albumin binding residues are known among linear and branched lipophilic moieties containing 4-40 carbon atoms having a distal acidic group.

EMBODIMENTS ACCORDING TO THE INVENTION

- 15 1. A method for making a GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of
- (i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue under suitable conditions for expression of said
20 precursor molecule,
 - (ii) separating the expressed precursor molecule from the culture broth,
 - (iii) coupling an N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the expressed precursor molecule,
 - (iv) isolating the resulting GLP-1 analogue or derivative by suitable means.
- 25 2. A method for making a GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

- i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue under suitable conditions for expression of said precursor molecule,
- ii) separating the expressed precursor molecule from the culture broth,
- 5 iii) protecting the lysine group(s) of the precursor molecule,
- iv) coupling an N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the protected precursor molecule, to obtain a protected GLP-1 analogue,
- v) deprotecting the lysine group(s) of the said protected GLP-1 analogue,
- 10 vi) isolating the resulting GLP-1 analogue or derivative by suitable means.

3. A method according to embodiments 1 or 2, wherein the N-terminal amino acid extension is protected before its use in the coupling step, where an N-terminal amino acid extension comprising one or more non-proteogenic amino acids is coupled to the protected precursor molecule, and wherein the protected GLP-1 analogue is deprotected again after coupling of the N-terminal extension.

15

4. A method for making a GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

- 20 i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue under suitable conditions for expression of said precursor molecule,
- ii) separating the expressed precursor molecule from the culture broth,
- iii) coupling a protected N-terminal amino acid extension comprising one or
- 25 more non-proteogenic amino acids to the expressed precursor molecule,
- iv) deprotecting any protecting group of the protected GLP-1 analogue or derivative,
- v) isolating the resulting GLP-1 analogue or derivative by suitable means.

30 5. A method for making a GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

- i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue under suitable conditions for expression of said precursor molecule,
- ii) separating the expressed precursor molecule from the culture broth,
- 5 iii) protecting the lysine group(s) of the precursor molecule,
- iv) coupling a protected N-terminal amino acid extension comprising one or more non-proteogenic amino acids to the protected precursor molecule, to obtain a protected GLP-1 analogue or derivative,
- v) deprotecting any protecting group of the protected GLP-1 analogue or
- 10 derivative,
- vi) isolating the resulting GLP-1 analogue or derivative by suitable means.

6. A method according to any of the previous embodiments, wherein the precursor molecule of said GLP-1 analogue is selected from the list of precursor
- 15 molecules comprising the amino acid sequence of the general formula:

Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-
Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-
Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅

wherein

- 20 Xaa₁₆ is Val or Leu;
Xaa₁₈ is Ser, Lys or Arg;
Xaa₁₉ is Tyr or Gln;
Xaa₂₀ is Leu or Met;
Xaa₂₂ is Gly or Glu;
- 25 Xaa₂₃ is Gln, Glu, Lys or Arg;
Xaa₂₅ is Ala or Val;
Xaa₂₆ is Lys, Glu or Arg;
Xaa₂₇ is Glu or Leu;
Xaa₃₀ is Ala, Glu or Arg;
- 30 Xaa₃₃ is Val, Lys or Arg;
Xaa₃₄ is Lys, Glu, Asn, His or Arg;

Xaa₃₅ is Gly;

Xaa₃₆ is Arg, Gly or Lys;

Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;

Xaa₃₈ is Lys, Ser, or is absent.

5 Xaa₃₉ is Ser, Lys, or is absent;

Xaa₄₀ is Gly, or is absent;

Xaa₄₁ is Ala, or is absent;

Xaa₄₂ is Pro, or is absent;

Xaa₄₃ is Pro, or is absent;

10 Xaa₄₄ is Pro, or is absent;

Xaa₄₅ is Ser, or is absent;

provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent then each amino acid residue downstream is also absent.

7. A method according to any of embodiments 1-5, wherein the precursor

15 molecule of said GLP-1 analogue is selected from the list of precursor molecules comprising the amino acid sequence of the general formula:

Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-
Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-
Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅

20 wherein

Xaa₉ is Glu or Asp

Xaa₁₀ is Gly or Ala

Xaa₁₆ is Val or Leu;

Xaa₁₈ is Ser, Lys or Arg;

25 Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys or Arg;

Xaa₂₅ is Ala or Val;

30 Xaa₂₆ is Lys, Glu or Arg;

Xaa₂₇ is Glu or Leu;

- Xaa₃₀ is Ala, Glu or Arg;
 Xaa₃₃ is Val, Lys or Arg;
 Xaa₃₄ is Lys, Glu, Asn, His or Arg;
 Xaa₃₅ is Gly;
 5 Xaa₃₆ is Arg, Gly or Lys;
 Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;
 Xaa₃₈ is Lys, Ser, or is absent.
 Xaa₃₉ is Ser, Lys, or is absent;
 Xaa₄₀ is Gly, or is absent;
 10 Xaa₄₁ is Ala, or is absent;
 Xaa₄₂ is Pro, or is absent;
 Xaa₄₃ is Pro, or is absent;
 Xaa₄₄ is Pro, or is absent;
 Xaa₄₅ is Ser, or is absent;
 15 provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent
 then each amino acid residue downstream is also absent.

8. A method according to any of embodiments 1-5, wherein the precursor molecule of said GLP-1 analogue is selected from the list of precursor molecules comprising the amino acid sequence of the general formula:

- 20 Xaa₈- Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-
 Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-
 Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅

wherein

- Xaa₈ is Ala, Gly, Val, Leu, Ile, Lys
 25 Xaa₉ is Glu, Asp
 Xaa₁₀ is Gly, Ala
 Xaa₁₆ is Val or Leu;
 Xaa₁₈ is Ser, Lys or Arg;
 Xaa₁₉ is Tyr or Gln;
 30 Xaa₂₀ is Leu or Met;
 Xaa₂₂ is Gly or Glu;

- Xaa₂₃ is Gln, Glu, Lys or Arg;
 Xaa₂₅ is Ala or Val;
 Xaa₂₆ is Lys, Glu or Arg;
 Xaa₂₇ is Glu or Leu;
 5 Xaa₃₀ is Ala, Glu or Arg;
 Xaa₃₃ is Val, Lys or Arg;
 Xaa₃₄ is Lys, Glu, Asn, His or Arg;
 Xaa₃₅ is Gly;
 Xaa₃₆ is Arg, Gly or Lys;
 10 Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;
 Xaa₃₈ is Lys, Ser, or is absent.
 Xaa₃₉ is Ser, Lys, or is absent;
 Xaa₄₀ is Gly, or is absent;
 Xaa₄₁ is Ala, or is absent;
 15 Xaa₄₂ is Pro, or is absent;
 Xaa₄₃ is Pro, or is absent;
 Xaa₄₄ is Pro, or is absent;
 Xaa₄₅ is Ser, or is absent;
 provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent
 20 then each amino acid residue downstream is also absent.

9. A method according to any of the previous embodiments, wherein the non-proteogenic amino acids in the N-terminal amino acid extension comprising one or more non-proteogenic amino acids, are selected from the group consisting of
 25 γ -carboxyglutamate, ornithine, phosphoserine, D-amino acids such as D-alanine and D-glutamine, D-alanine and D-leucine, Aib (α -aminoisobutyric acid), Abu (α -aminobutyric acid), Tle (tert-butylglycine), 3-aminomethyl benzoic acid, anthranilic acid, des-amino-Histidine, β -alanine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N α -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine, 4-
 30 pyridylalanine, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, (1-aminocyclooctyl)

carboxylic acid, α -methyl prolin, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine.

10. A method according to any of the previous embodiments, wherein the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 1 amino acid.
11. A method according to any of embodiments 1-9, wherein the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 2 amino acids.
12. A method according to any of embodiments 1-9, wherein the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 3 amino acids.
13. A method according to any of embodiments 1-9, wherein the length of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids is 4 amino acids.
14. A method according to any of the previous embodiments, wherein the N-terminal amino acid extension comprises two non-proteogenic amino acids.
15. A method according to any of embodiments 1-13, wherein the N-terminal amino acid extension comprises three non-proteogenic amino acids.
16. A method according to any of embodiments 1-13, wherein the N-terminal amino acid extension comprises four non-proteogenic amino acids.
17. A method according to any of the previous embodiments, wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula
- Xaa₇-Xaa₈- Xaa₉- Xaa₁₀

wherein

Xaa₇ is selected from L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N ^{α} -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and
5 4-pyridylalanine, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine

Xaa₈ is selected from Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid and alpha-methyl proline
10

Xaa₉ is selected from Glu, Asp, γ,γ -dimethyl Glu, β,β -dimethyl Glu and β,β -dimethyl Asp, and

Xaa₁₀ is selected from Gly, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, and (1-aminocyclooctyl) carboxylic acid.
15

18. A method according to any of embodiments 1-16, wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

20 Xaa₇-Xaa₈

wherein

Xaa₇ is selected from L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N ^{α} -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and
25 4-pyridylalanine; 1-methyl histidine, 3-methyl histidine, 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine; and

Xaa₈ is selected from Gly, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid and alpha-methyl proline

- 5 19. A method according to any of embodiments 1-16, wherein the N-terminal amino acid extension comprising one non-proteogenic amino acid having the general formula

Xaa₇

wherein

- 10 Xaa₇ is selected from D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N^α-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine; 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β-(1,2,4-triazol-1-yl)-alanine.
- 15 20. A method according to embodiment 19, wherein the N-terminal amino acid extension is desamino-histidine and the coupling reaction is carried out by a 4-[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-ethyl]-1H-imidazol-1-ium salt, such as trifluoroacetate, with the expressed precursor molecule.
- 20 21. A method according to any of embodiments 1-5, wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

Xaa₇-Xaa₈- Xaa₉- Xaa₁₀ as defined in embodiment 17;

and the GLP-1 analogue has the general formula

Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-
Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-
Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ as defined in embodiment 3.

22. A method according to any of embodiments 1-5, wherein the N-terminal
amino acid extension comprising one or more non-proteogenic amino acids has
the general formula

Xaa₇-Xaa₈ as defined in embodiment 18;

and the GLP-1 analogue has the general formula

Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-
Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-
Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ as defined in embodiment 4.

23. A method according to any of embodiments 1-5, wherein the N-terminal
amino acid extension comprising one or more non-proteogenic amino acids has
the general formula

Xaa₇ as defined in embodiment 19;

and the GLP-1 analogue has the general formula

Xaa₈- Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-
Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-
Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅ as defined in

embodiment 4.

24. A method according to any of embodiments 17-23, wherein the C-terminal
non-proteogenic or proteogenic amino acid in the N-terminal extensions Xaa₇-
Xaa₈-Xaa₉-Xaa₁₀ or Xaa₇-Xaa₈, or the non-proteogenic amino acid Xaa₇ is
activated.

25. A method according to embodiment 24, wherein the activated amino acid(s)
are selected from the group consisting of: acid chloride, acid bromide, acid

fluoride, symmetrical anhydride, mixed anhydride, carboxylic acids activated using common carbodiimides, carboxylic acids using carbodiimides and an additive and carboxylic acids activated with an uronium salt or a phosphonium salt.

- 5 26. A method according to embodiment 24, wherein the activated amino acid(s) are selected from the group consisting of: carboxylic acids activated using common carbodiimides, diisopropylcarbodiimide (DIPCDI), *N,N'*-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride (EDC).
- 10 27. A method according to embodiment 24, wherein the activated amino acid(s) are selected from the group consisting of: carboxylic acids using carbodiimides and an additive selected from the group consisting of *N*-hydroxybenzotriazol (HOBt), 1-Hydroxy-7-azabenzotriazole, 6-chloro-*N*-hydroxybenzotriazol (HOAt) and 3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (DhbtOH),
- 15 28. A method according to embodiment 24, wherein the activated amino acid(s) are selected from the group consisting of: carboxylic acids activated with an uronium salt or a phosphonium salt, *O*-Benzotriazole-*N,N,N',N'*-tetramethyl-uronium-hexafluoro-phosphate (HBTU), *O*-(Benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU), 2-(1*H*-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate (HATU), 1-benzotriazolyoxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PYBOP), esters of *N*-hydroxysuccinimid (NHS ester), pentafluorophenol ester (PfP-ester), 2,4-dinitrophenyl ester, 4-nitrophenyl ester, 3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (HODhbt) Carbonyldiimidazole (CDI), *N*-ethyl-5-phenylisoxazolium-3'-sulfonate (NEPIS).
- 25 29. A method according to any of the previous embodiments, wherein the coupling of the *N*-terminal amino acid extension comprising one or more non-proteogenic amino acids takes place in an organic polar solvent selected from

the group consisting of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide *N,N*-dimethylformamide and *N*-methyl-formamide.

30. A method according to any of the previous embodiments, wherein the coupling of the N-terminal amino acid extension comprising one or more non-
5 proteogenic amino acids takes place in an aqueous solvent mixture.

31. A method according to embodiment 30, wherein the aqueous solvent mixture comprises an organic polar solvent selected from the group consisting of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide *N,N*-dimethylformamide and *N*-methyl-formamide.

10 32. A method according to embodiments 30 or 31, wherein the coupling of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids takes place in an aqueous solvent mixture, wherein the pH in the reaction mixture is between 4 and 12, preferably between 6 and 10.

15 33. A method according to any of the previous embodiments, wherein the amino acids in the N-terminal amino acid extension comprising one or more non-proteogenic amino acids comprises one or more protection groups.

34. A method according to embodiment 33, further comprising the step of removing one or more protection groups from said N-terminal amino acid extension comprising one or more non-proteogenic amino acids.


20 35. A method according to embodiment 1, further comprising the step of acylating the epsilon-amino-group of at least one lysine residue in the expressed precursor molecule with an acylating agent.

36. A method according to embodiment 35, wherein the acylating agent is a carboxylic acid analogue of the general formula;

25 A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH
which is optionally activated and/or protected with one or more protection group(s),


wherein

A is selected from the group consisting of;




- 5 wherein n is selected from the group consisting of 14, 15, 16, 17, 18 and 19, p is selected from the group consisting of 10, 11, 12, 13 and 14, and d is selected from the group consisting of 0, 1, 2, 3, 4 and 5, and m is selected from the group consisting of 11, 12, 13, 14, 15, 16, 17, k is selected from the group consisting of 0, 1, 2, 3, 4, 5, 11 and 27, and m is selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6, and R¹ is selected from the group of 9H-fluoren-9-ylmethoxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc), Benzylcarbamate (Cbz).
- 10

B is selected from the group consisting of









wherein x is selected from the group consisting of 0, 1, 2, 3 and 4, and y is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12,

C is selected from the group consisting of



wherein b and e are each independently selected from the group consisting of 0, 1 and 2, and c and f are each independently selected from the group consisting of 0, 1 and 2 with the proviso that b is 1 or 2 when c is 0, or b is 0 when c is 1 or 2, and e is 1 or 2 when f is 0, or e is 0 when f is 1 or 2, and

D is selected from the group consisting of



and wherein k is selected from the group consisting of 0, 1, 2, 3, 4, 5, 11 and 27, and m is selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6.

37. A method according to embodiment 36, wherein the the carboxylic acid A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH is activated to activated acylating agent.

38. A method according to embodiment 35, wherein said acylation step takes place in an aqueous solvent mixture.

39. A method according to embodiment 38, wherein said aqueous solvent mixture comprises an organic polar solvent.

40. A method according to embodiment 39, wherein said organic polar solvent is selected from the group consisting of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-dimethylformamide and *N*-methyl-formamide.

41. A method according to embodiment 40, wherein the amount of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-dimethylformamide or *N*-methyl-formamide is less than 80% (v/v).

42. A method according to embodiment 40, wherein the amount of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-dimethylformamide or *N*-methyl-formamide is less than 50% (v/v).

43. A method according to embodiment 40, wherein the amount of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide, *N,N*-dimethylformamide or *N*-methyl-formamide is in the range of about 40-80% (v/v).

44. A method according to embodiment 35, wherein the acylating agent is added to the reaction mixture as a solid.

45. A method according to embodiment 35, wherein said acylation step takes place in an aqueous solvent mixture, wherein the pH in the reaction mixture is between 9 and 13, preferably between 10 and 12 or even more preferably between 10.5 and 11.5.

5 46. A method according to embodiment 35, wherein the acylating agent, which is optionally activated, comprises one or more protection groups.

47. A method according to embodiment 46, further comprising the step of removing one or more protection groups from said activated acylating agent.

10 48. A method according to any of the previous embodiments, further comprising the step of removing an N-terminal pro-peptide extension from the resulting precursor molecule.

49. A method according to any of embodiments 1-47, further comprising the step of removing a C-terminal pro-peptide extension from the resulting precursor molecule.

15 50. A method according to any of the previous embodiments, wherein the host cell is a mammalian host cell.

51. A method according to any of embodiments 1-49, wherein the host cell is a bacterial host cell.

20 52. A method according to any of embodiments 1-49, wherein the host cell is a yeast host cell.

53. A method according to embodiment 52, wherein the yeast host cell is *Saccharomyces cerevisiae*.

25 54. A method according to any of the previous embodiments, wherein the GLP-1 analogue is an analogue or derivative of human GLP-1(7-37), human GLP-2, exendin-3 or exendin-4.

55. A method according to any of the previous embodiments, wherein the GLP-1 analogue is an analogue or derivative of human GLP-1(7-37).

56. A method according to any of the previous embodiments, wherein said GLP-1 analogue is selected from the group consisting of Aib⁸-GLP-1(7-36)-amide,

- 5 Aib⁸-GLP-1(7-37), Aib^{8,35} GLP-1(7-37), [Aib⁸,Arg³⁴]GLP-1-(7-37),
 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37),
 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
 [DesaminoHis⁷,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
 [DesaminoHis⁷,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
 10 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37),
 [DesaminoHis⁷,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37),
 [DesaminoHis⁷,Glu²²,Arg²⁶,Glu³⁰,Arg³⁴,Lys³⁷]GLP-1-(7-37),
 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1(7-37)amide,
 [DesaminoHis⁷,Arg³⁴]GLP-1-(7-37), [Aib⁸,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-
 15 37)amide,
 [DesaminoHis⁷, Glu²² Arg²⁶, Arg³⁴, Phe(m-CF₃)²⁸]GLP-1-(7-37)amide,
 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴]GLP-1-(7-37)-Lys,
 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴]GLP-1-(7-37)-Lys,
 [dDesaminoHis⁷,Arg²⁶,Arg³⁴,]GLP-1-(7-37)-Lys,
 20 [DesaminoHis⁷,Glu²²,Arg²⁶,Arg³⁴,Lys³⁷]GLP-1-(7-37)amide,
 and analogues thereof.

57. A method according to any of the previous embodiments, wherein the GLP-1 analogue is the only biologically active substance in the pharmaceutical composition.


- 25 58. A method according to any of the previous embodiments, wherein the GLP-1 analogue is an exendin-4 analogue.

59. The method according to any of the previous embodiments comprising a step of selectively protecting the epsilon-amino-group of at least one lysine residue.


60. The method according to embodiment 59 wherein the step is added after step (ii) separating the expressed precursor molecule from the culture broth.

61. The method according to embodiment 59 wherein the step is added after step (iv) as defined in embodiment 1 isolating the resulting GLP-1 analogue or derivative by suitable means.

62. The method according to embodiment 19, wherein the N-terminal amino acid is desamino-histidine introduced by the activated acylating agent 4-{3-[(2,5-dioxo-1-pyrrolidinyloxy)-3-oxopropyl]-1Himidazol-1-ium



63. The method according to embodiment 19, wherein the N-terminal amino acid is desamino-histidine introduced by the use of the activated acylated agent 4-{3-[(2,5-dioxo-1-pyrrolidinyloxy)-3-oxopropyl]-1Himidazol-1-ium trifluoroacetate



64. The method according to any of the previous embodiments, wherein the coupling of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids takes place in an organic polar solvent selected from the group consisting of 1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide *N,N*-dimethylformamide and *N*-methyl-formamide.


65. The method according to any of embodiments 1-63, wherein the coupling of the N-terminal amino acid extension comprising one or more non-proteogenic amino acids takes place in an aqueous solvent mixture.

66. The method according to embodiment 65, wherein the aqueous solvent mixture comprises an organic polar solvent selected from the group consisting of

1-methyl-pyrrolidin-2-one, acetonitril, tetrahydrofuran, dimethylsulfoxide *N,N*-dimethylformamide and *N*-methyl-formamide.


67. The method according to any of embodiments 1-63, wherein the coupling of the N-terminal amino acid extension comprising one or more non-proteogenic
5 amino acids takes place in an aqueous solvent mixture, wherein the pH in the reaction mixture is between 7 and 11, preferably between 8 and 10.

68. A method of introducing des-amino histidine in a insulinotropic agent with the use of the activated acylating agent 4-{3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropyl}-1*H*imidazol-1-ium:



10

69. A method of introducing des-amino histidine in a insulinotropic agent with the use of the activated acylated agent 4-{3-[(2,5-dioxo-1-pyrrolidinyl)oxy]-3-oxopropyl}-1*H*imidazol-1-ium trifluoroacetate



15

The present invention will now be described in more details in the following non-limiting Examples and Drawings.

20 **EXAMPLES**

Abbreviations used:

	Adoc:	adamantyloxycarbonyl
	Aib:	α -aminoisobutyric acid
	Boc:	tert butyloxycarbonyl
	CH ₃ CN:	acetonitrile
5	DCM:	dichloromethane
	DIC:	Diisopropylcarbodiimide
	DIPEA:	diisopropylethylamine
	DMF:	<i>N,N</i> dimethylformamide
	EtOAc:	Ethylacetate
10	Et ₂ O:	diethylether
	Fmoc:	9 H-fluoren-9-ylmethoxycarbonyl
	HATU:	2-(7-azabenzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexafluorophosphate
	HBTU:	2-(1H-Benzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexafluorophosphate
15	H ₂ O:	water
	HOAt:	1-Hydroxy-7-azabenzotriazole
	HOBt:	1-Hydroxybenzotriazole
	MeCN:	acetonitrile
20	Mtt:	4-Methyltrityl
	MW:	Molecular weight
	NaOH:	Sodium hydroxide
	NHS:	N-Hydroxysuccinimide
	NMP:	1-Methyl-pyrrolidin-2-one
25	OtBu:	tert butyl ester
	PyBoP	(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
	PyBroP	bromo-tris-pyrrolidinophosphonium hexafluorophosphate
	r.t:	room temperature
30	OSu:	N-Hydroxysuccinimide ester
	tBu:	tert-butyl
	TBME:	tert-butylmethylether
	TEA:	triethylamine

	TFA:	trifluoroacetic acid
	TFFH	Tetramethylfluoroformamidinium hexafluorophosphate
	TIPS:	triisopropylsilane
	Trt:	Trityl, triphenylmethyl
5	TSTU:	O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate

General methods

General method for the preparation of peptides (method A)

The peptide can be synthesized according to the Fmoc strategy on an Applied Biosystems 433 peptide synthesizer in 0.25 mmol or 1.0 mmol scale using the manufacturer supplied FastMoc UV protocols which employ HBTU (2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) or HATU (O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) mediated couplings in NMP (N-methyl pyrrolidone), and UV monitoring of the deprotection of the Fmoc protection group. Wang or trityl based resins can be used as solid support and the protected amino acid derivatives used is standard Fmoc-amino acids (supplied from e.g. Anaspec, or Novabiochem) supplied in preweighed cartridges suitable for the ABI433A synthesizer. The N terminal amino acid is Boc protected at the alpha amino group (e.g. Boc-His(Boc)OH is used for peptides with His at the N-terminal). The synthesis of the peptides may in some cases be improved by the use of dipeptides protected on the dipeptide amide bond with a group that can be cleaved under acidic conditions such but not limited to 2-Fmoc-oxy-4-methoxybenzyl or 2,4,6-trimethoxybenzyl. In cases where a serine or a threonine is present in the peptide, the use of pseudoproline dipeptides may be used (see e.g. catalogue from Novobiochem 2002/2003 or newer version, or W.R. Sampson (1999), J. Pep. Sci. 5, 403).

General method for the preparation of peptides (method B)

One alternative method of peptide synthesis is by Fmoc chemistry on a microwave-based Liberty peptide synthesizer (CEM Corp., North Carolina). Wang or trityl based resins can be used as solid support. The coupling chemistry is performed with DIC/HOAt in NMP using amino acid solutions of 0.4 M in NMP and a

molar excess of 8-10 fold. Coupling conditions is 5 minutes at up to 70°C. Deprotection is achieved with 5% piperidine in NMP at up to 70°C.

The GLP-1 precursor molecules can e.g. be purified by a variety of chromatographic procedures, e. g. ion exchange chromatography, hydrophobic interaction chromatography, gel filtration chromatography, affinity chromatography, reverse phase HPLC or the like, dependent on the type of polypeptide in question.

General method for the preparation of acylating agents A-OH A-B-C-D-OH, A-C-D-OH, A-B-C-OH and N-terminal amino acid extensions Xaa₇-Xaa₈-Xaa₉-Xaa₁₀,

10 Xaa₇-Xaa₈ and Xaa₇

The necessary carboxylic acids can be prepared on a 2-chlorotritylchloride resin using standard Fmoc chemistry. First Fmoc protected amino carboxylic acid can be attached to the 2-chlorotritylchloride resin by swelling the resin in a suitable solvent like NMP, DCM, DMF or the like, preferably DCM. The adequately protected Fmoc amino carboxylic acid is added together with a suitable base such as DIPEA or TEA, and the resin is agitated for a suitable period of time such as 30 min at r.t. The resin is washed with a suitable solvent such as NMP, DMF or DCM.

Fmoc deprotection is achieved using piperidine in NMP, preferably 20% piperidine in NMP at r.t. for 1 to 30 min, typically 10 min, before the resin is washed thoroughly with NMP, DMF or DCM. The step is repeated until complete deprotection is obtained, typically 3 times or more.

Coupling of the next Fmoc protected amino carboxylic acid is achieved using standard coupling conditions; the resin is swelled in a solvent like NMP, DMF, DCM or a mixture of these. Another solution of Fmoc protected amino carboxylic acid in a solvent like NMP, DMF, DCM or a mixture of these and HOBt or HOAt is added DIC or an equivalent of such. This mixture is added to the resin and the mixture is added DIPEA or TEA and the mixture is agitated at r.t. for 1 to 16 hours typically 3 hours. Alternatively, the mixture is agitated for 1 to 60 min

before DIPEA or TEA is added to the mixture. If the coupling is not completed judged by TNBS test, ninhydrine test or choranyl test the step is repeated until negative test.

Alternatively activation of the Fmoc protected amino carboxylic acid can be
5 achieved using the following coupling reagents; PyBOP, PyBrOP, HBTU, HATU, or TFFH.

Further incorporation of adequately protected Fmoc-amino carboxylic acids can be introduced using the procedure given above. The last coupling step comprising incorporation of a carboxylic acid derivative is introduced using the
10 coupling conditions described above.

Cleavage from the resin can be achieved by treatment of the resin with 20% trifluoroethanol in DCM, DCM-TIPS-TFA (95.5:2.5:2) or hexafluoroisopropanol from 5 min to 3 hours to give the fully protected derivative.

Cleavage from the resin can also be achieved using TFA-TIPS-Water
15 (95:2.5:2.5) from 5 min to 3 hours to give the fully deprotected derivatives.

Alternatively the derivatives can be prepared in solution using standard procedures described in the literature.

Appropriately protected building blocks are commercially available or can be prepared using procedures described in the literature.

20 Xaa₇ is commercially available or can be prepared via procedures described in the literature.

General method for activation of acylating agents A-OH A-B-C-D-OH, A-C-D-OH, A-B-C-OH and N-terminal amino acid extensions Xaa₇-Xaa₈-Xaa₉-Xaa₁₀, Xaa₇-Xaa₈ and Xaa₇

Activation of the required amino acids can be achieved using standard procedures described in the literature. If an active ester such as an *N*-hydroxy succinimid ester is required the carboxylic acid is dissolved in an appropriate solvent such as THF, ethyl acetate, NMP or DMF. A reagent such as *O*-(*N*-succinimidyl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate is added to the solution together with a base such as DIPEA or TEA. The mixture is stirred at r.t. until the reaction is complete typically from 3 to 16 hours. Alternatively the carboxylic acid can be dissolved together with *N*-hydroxy succinimide and treated with DIC. The product mixture can be used directly without further purification or it can be subjected an aqueous work up.

Purification

The crude peptide was purified by preparative HPLC on a column packed with C18 silica. After drying the crude peptide was dissolved in 50% acetic acid in H₂O, diluted with H₂O and injected on the column which then was eluted with a gradient of CH₃CN in water and 0.1% TFA 10 ml/min during 50 min at 40 °C. The fractions containing the peptide were collected and lyophilized after dilution with water.

Analysis

LCMS

LCMS was performed on a setup consisting of Sciex API 100 Single quadropole mass spectrometer. The instrument control and data acquisition were done by the Sciex Sample control software running on a Windows 2000 computer. The HPLC pump is connected to two eluent reservoirs containing:

A: 0.05% Trifluoro acetic acid in water

B: 0.05% Trifluoro acetic acid in acetonitrile

The analysis was performed at room temperature by injecting an appropriate volume of the sample (preferably 20 µl) onto the column which was eluted with a gradient of acetonitrile.

The HPLC conditions, detector settings and mass spectrometer settings used are giving in the following table:

Column: Waters Xterra MS C-18 X 3 mm id 5 μ m

Gradient: 5% - 90 % acetonitrile linear during 7.5 min at 1.5ml/min

5 Detection: 210 nm (analogue output from DAD)

ELS (analogue output from ELS): 40 °C

MS ionisation mode: API-ES

HPLC

- 10 Method 01_B4_2: RP-analysis was performed using a Waters 600S system fitted with a Waters 996 diode array detector. UV detections at 214nm and 254nm were collected using a Symmetry 300 C18, 5 μ m, 3.9 mm x 150 mm column, 42 °C. Eluted with a linear gradient of 5-95% acetonitrile, 90-0% water, and 5% trifluoroacetic acid (1.0%) in water over 15 minutes at a flow-rate of 1.0 min/min.
- 15 Method 02_B4_4: The RP-analyses was performed using a Alliance Waters 2695 system fitted with a Waters 2487 dualband detector. UV detections at 214nm and 254nm were collected using a Symmetry300 C18 , 5 μ m, 3.9 mm x 150 mm column, 42 °C. Eluted with a linear gradient of 5-95% acetonitrile, 90-0% water, and 5% trifluoroacetic acid (1.0%) in water over 15 minutes at a flow-rate of
- 20 1.0 min/min.

EXAMPLE 1

Construction of yeast expression systems and production of GLP-1 analogue precursor molecules (R34)GLP-1(8-37)

Expressions plasmids are of the C-POT type, similar to those described in EP 171,142. These are 2 μ -based expression vectors characterized by containing the *Schizosaccharomyces pombe* triose phosphate isomerase gene (POT) for the purpose of plasmid selection and stabilization in *S. cerevisiae*. The plasmids also contain the *S. cerevisiae* triose phosphate isomerase promoter and terminator (Figure 1). These sequences are similar to the corresponding sequences in plasmid pKFN1003 (described in WO 90100075) as are all other sequences except the following: 1) The sequence of the EcoRI-XbaI fragment encoding the fusion protein of the leader and the insulin product. 2) A silent mutation has been introduced resulting in removal of a NcoI-site in the 2 μ -region in the expression vector. In order to facilitate cloning of different fusion proteins a the DNA sequence encoding the MF α 1 pre-pro leader has been changed to incorporate a NcoI site (see Figure 2) and is called the MF α 1* pre-pro leader. Thus the NcoI-XbaI fragment is simply replaced by an NcoI-XbaI fragment encoding the GLP-1 precursor molecule of interest. Such NcoI-XbaI fragments may be synthesized using synthetic oligonucleotides and PCR according to standard techniques. In addition to the alpha-leader other leaders can be used.

Synthetic DNA fragments containing sequences encoding (R34)GLP-1(11-37), (E22,R26,R34)GLP-1(8-37)K38 and (E22,R26,R34,K37)GLP-1(8-37) were obtained from Genart AG, BioPark, Josef-Engert-Str. 11, D-93053 Regensburg, Germany. The synthetic DNA encoding (E22,R26,R34)GLP-1(8-37)K38 and (E22,R26,R34,K37)GLP-1(8-37) was furnished with 3' and 5' DNA sequences encoding N- and C-terminal extension to facilitate expression in yeast (Figure 2) and termed Ext1-(E22,R26,R34)GLP-1(8-37)K38-Ext2 and Ext1-(E22,R26,R34,K37)GLP-1(8-37)-Ext2. The synthetic DNA was digested with NcoI and XbaI and ligated to the NcoI – XbaI vector fragment of the modified cPOT type expression vector (figure 1). This resulted in three expression plasmids pSA273, pSA277 and pSA278 encoding (R34)GLP-1(11-37) (SEQ ID NO:6), Ext1-(E22,R26,R34)GLP-1(8-37)K38-Ext2 (SEQ ID NO:7) and Ext1-(E22,R26,R34,K37)GLP-1(8-37)-Ext2 (SEQ ID NO:8), respectively.

The expression plasmids were propagated in *E. coli*, grown in the presence of ampicillin and isolated using standard techniques (Sambrook et al., 1989). The

plasmid DNA was checked for insert by appropriate restriction nucleases (e.g. *EcoRI*, *NcoI*, *XbaI*) and was shown by sequence analysis to contain the proper sequence of the GLP-1 analogue precursors molecules (R34)GLP-1(11-37), Ext1-(E22,R26,R34)GLP-1(8-37)K38-Ext2 and Ext1-(E22,R26,R34,K37)GLP-1(8-37)-Ext2. (Figure 2).

The plasmids were transformed into *S. cerevisiae* strain ME1719 (MATa/ α leu2/leu2 pep4-3/pep4-3 Δ tpi::LEU2/ Δ tpi::LEU2 Δ ura3/ Δ ura3 Δ yps1::URA3 / Δ yps1::ura3 Cir+). This strain is described in WO 98/01535. Yeast transformants harbouring the plasmid were selected by glucose utilization as carbon source on YPD (1% yeast extract, 2% peptone, 2% glucose) agar (2%) plates. This resulted in three yeast strains: ySA251, ySA259 and ySA260 expressing (R34)GLP-1(11-37) (SEQ ID NO:9), Ext1-(E22,R26,R34)GLP-1(8-37)K38-Ext2 (SEQ ID NO:10) and Ext1-(E22,R26,R34,K37)GLP-1(8-37)-Ext2 (SEQ ID NO:11), respectively.

The ME1719 yeast strains ySA251, ySA259 and ySA260 were inoculated into 5 ml of growth media, for example a medium consisting of 5 g/L (NH₄)₂SO₄, 184 mg/L (NH₄)₂HPO₄, 2.88 g/L KH₂PO₄, 1.42 g/L MgSO₄·7H₂O, 1.28 g/L, K₂SO₄, 10.00 g/L succinic acid, 10.00 g/L casamino acids, 0.0112 g/L FeSO₄·7H₂O, 0.0086 g/L MnSO₄·H₂O, 0.0014 g/L CuSO₄·5H₂O, 0.00185 g/L ZnSO₄·7H₂O, 0.0129 g/L CaCl₂·2H₂O, 0.071 g/L citric acid, 28.0 mg/L m-inositol, 14.0 mg/L choline chloride, 2.8 mg/L thiamine, 2.8 mg/L niacinamide, 2.1 mg/L Ca-pantothenic acid, 0.14 mg/L biotin, 0.14 mg/L folic acid, 40 g/L glucose. The cultivation was carried out at 30°C for 3 days. After centrifugation the supernatant was removed for quantitative HPLC analysis by which method the concentration of secreted GLP-1 analogue was measured. The identity of the GLP-1 precursor molecules was confirmed by LC/MS analysis. The N- and C-terminal extensions employed to facilitate expression of (E22,R26,R34)GLP-1(8-37)K38 and (E22,R26,R34,K37)GLP-1(8-37) were removed by the lysine specific *Achromobacter Lyticus* Protease 1 according to well-established procedures.

EXAMPLE 2Construction of yeast expression system and production of GLP-1 analogue precursor molecule (R34)GLP-1(9-37)

A synthetic DNA fragment encoding (R34)GLP-1(9-37) was constructed by
5 standard PCR using the primers 5'-
AGGGGTATCCATGGCTAAGAGAGAAGGTACCTTCACCTCTGAC-3' and 5'-
AATCTTAGTTTCTAGAGCCTGCG-3' and a plasmid containing DNA sequence
encoding (R34)GLP-1(7-37). The primers were designed an 5' NcoI site and a 3'
XbaI site. Thus the PCR fragment could be digested by NcoI and XbaI after
10 purification and ligated to the NcoI – XbaI vector fragment of the modified cPOT
type expression vector described in example 1. The resulting plasmid encoding
(R34)GLP-1(9-37) was named pSA82.

The expression plasmid was propagated in *E. coli*, grown in the presence of
ampicillin and isolated using standard techniques (Sambrook et al., 1989). The
15 plasmid DNA was checked for insert by appropriate restriction nucleases (e.g.
EcoRI, *NcoI*, *XbaI*) and was shown by sequence analysis to contain the proper
sequence of the GLP-1 analogue precursors molecule (R34)GLP-1(9-37).

The plasmid was transformed into *S. cerevisiae* strain ME1719 and a yeast
transformant harbouring the plasmid was selected as described in example 1.
20 The resulting yeast strain expressing (R34)GLP-1(9-37) was named ySA96.

The yeast strain was cultivated in growth media and (R34)GLP-1(9-37) was
recovered from the media as described in example 1.

EXAMPLE 3Construction of yeast expression systems for GLP-1 precursors

25 The leader and Kex2p cleavage sites were optimized in order to augment
expression yield of processed, secreted peptide. Synthetic DNA fragments
encoding various leader and (R34)GLP-1(11-37), or (R34)GLP-1(9-37)
constructs were amplified by standard PCR. The forward primers included an
NcoI-site and the sequence encoding the optimized leader sequence. The

reverse primers included an *Xba*I-site. Hence, allowing cloning of the *Nco*I-*Xba*I restricted PCR-fragments into the *Nco*I-*Xba*I restricted cPOT-type expression vector. Refer to figure 4 for sequences, plasmid numbering of (R34)GLP-1(11-37) encoding expression construct and strain names.

- 5 Expression plasmids were propagated in *E. coli* in the presence of ampicillin and isolated using standard techniques (Sambrook et al., 1989). Plasmid constructs were checked by restriction endonuclease digestion using appropriate restriction enzymes. Encoding sequences were sequence verified.

10 Plasmids were transformed into the *S. cerevisiae* strain ME1719. Yeast cells harboring the plasmid were selected as described in example 1. Cultivation of the yeast strains was essentially as described in example 1

Optimization of the sequence in the vicinity of the Kex2p cleavage-site, P1 to P6, led to a modest increase in yield (figure 4: B). Incorporation of a Proline in the sequence (P3 to P6) was explored as a potential means of increasing exposure of the Kex2p cleavage site to Kex2p. Although, this turned out to not to be the case for (R34)GLP-1(11-37) a beneficial effect may be observed for (R34)GLP-1(11-37) (figure 4: H, I). Variation of residues P7 to P11 had a pronounced effect on expression yield, 2-2.5 fold increases were observed when motifs containing charged amino acids were introduced (figure 4: M-Z, K5-7, L2-4). A series of constructs had been designed for processing with DAP-1 (dipeptidyl aminopeptidase) in the downstream process (figure 4: G, J, K, L). Constructs J and L contain a Q in the position before Thr-11, to protect against promiscuous cleavage by DAP-1 of the GLP-1 peptide. This Gln can subsequently be removed using the enzymes Q-cyclase and pGAPase (Qiagen).

25

Table 1.


SEQUENCE	SEQUENCE REF.	YIELD	PLASMID	STRAIN NAME
•RARYKR	(A)	25	pISNN546	SCI50

•RDLGKR	(B)	125	pISNN547	SCI51
•RDLAKR	(C)	88	pISNN548	SCI52
•RARAKR	(D)	58	pISNN549	SCI53
•RALDKR	(E)	58	pISNN550	SCI54
•RALAKR	(F)	43	pISNN551	SCI55
•PRDLGKR	(H)	68	pISNN585	SCI57
•RPLGKR	(I)	58	pISNN586	SCI58
•RDLGKREA	(G)	200	pISNN589	SCI56
•RDLGKREAQ	(J)	188	pISNN599	SCI59
•RDLGKREAEA	(K)	240	pISNN590	SCI60
•RDLGKREALEKR	(K5)	n.d.	pISNN654	
•RDLGRREALEKR	(K6)	n.d.	pISNN655	
•RDLGEALEKR	(K7)	100	pISNN652	
•RDLGKREAEAQ	(L)	253	pISNN587	SCI44
•RDLGKREAEAQKR	(L2)	25	pISNN650	
•RDLGRREAEAQKR	(L3)	n.d.	pISNN656	
•RDLGEAEAQKR	(L4)	13	pISNN651	
•ERLERDLGKR	(M)	225	pISNN610	SCI63
•KERLERDLGKR	(N)	100	pISNN611	SCI64
•ERLEKR	(O)	138	pISNN617	SCI65

•KERLEKR	(P)	125	pISNN612	SCI66
•PERLERDLGKR	(Q)	73	pISNN613	SCI67
•PERLEKR	(R)	125	pISNN614	SCI68
•EAEARDLGKR	(S)	175	pISNN615	SCI69
•PEAEARDLGKR	(T)	100	pISNN616	SCI70
•EEAEKR	(U)	125	pISNN623	SCI71
•EEAERDLGKR	(V)	218	pISNN624	SCI72
•RDLGEEAEKR	(X)	218	pISNN625	SCI73
•EEAELAKR	(Y)	165	pISNN626	SCI74
•EEAELGKR	(Z)	105	pISNN627	SCI75
•KR		100	pISNN545	SCI43

EXAMPLE 4

5 Preparation of N-terminal extension Boc-His(Boc)-Aib-Glu(O-tBu)-Gly-OH



2-chlorotritylchloride resin (1% DVB, 1.4 mmol/g, 10 g, 14.0 mmol) was pre-swelled in DCM before it was added a solution of Fmoc-Gly-OH (8,3 g, 28 mmol) and DIPEA (9,03 g, 70 mmol) in 100 mL DCM, and agitated for 30 min at r.t.. The resin was washed with NMP (2 x 100 mL) and 2 x 100 mL DCM-MeOH-DIPEA (80:15:5, 10 min) then NMP (3 x 100 mL), before treatment with 20% piperidine in NMP (3 x 100 mL) for 10 min each. The resin was washed with NMP (6 x 100 mL), DCM (2 x 100 mL) and MeOH (2 x 100 mL) and dried over night *in vacuo*. The resin was treated with 100 mL 20% piperidine in NMP for 10 min. The step was repeated twice before it was washed with NMP (5 x 100 mL).

- 10 Fmoc-Glu(O-tBu)-OH (23.8 g, 56 mmol) was dissolved in a mixture of 100 mL NMP and 20 mL DCM. HOAt (7.62 g, 56 mmol) was added followed by drop wise addition of DIC (7.07 g, 56 mmol). The mixture was stirred for 15 min before DIPEA (9.03 g, 70 mmol) was added, and the mixture was transferred to the resin. The resin was agitated for 16 h before it was washed with NMP (4 x 100 mL). The resin was treated with 20% piperidine in NMP (100 mL) for 10 min. The step was repeated twice before it was washed with NMP (5 x 100 mL).

- 20 Fmoc-Aib-OH (18.22 g, 56 mmol) was dissolved in a mixture of 100 mL NMP and 20 mL DCM. HOAt (7.62 g, 56 mmol) was added followed by drop wise addition of DIC (7.07 g, 56 mmol). The mixture was stirred for 20 min before it was added to the resin. The mixture was agitated for 30 min before DIPEA was added. The mixture was agitated for 16 h before the resin was washed with NMP (4 x 100 mL). The resin was treated with 20% piperidine in NMP (100 mL) for 10 min. The step was repeated twice before it was washed with NMP (5 x 100 mL).

- 25 Boc-His(Boc)-OH (19.9 g, 56 mmol) was dissolved in a mixture of 100 mL NMP and 20 mL DCM. HOAt (7.62 g, 56 mmol) was added followed by drop wise addition of DIC (7.07 g, 56 mmol). The mixture was stirred for 20 min before it was added to the resin. The mixture was agitated for 30 min before DIPEA was added. The mixture was agitated for 16 h before the resin was washed with NMP (3 x 100 mL), DCM (4 x 100 mL).

Trifluoroethanol-DCM (1:4, 125 mL) was added and the resin was agitated for 1 hour. The filtrate was collected and a new portion of trifluoroethanol-DCM (1:4, 125 mL) was added and agitated for 15 min. The filtrate was collected and the solvent was removed *in vacuo* to give a clear oil. Ice cold diethyl ether (300 mL) was added whereupon a white precipitate was formed. Light petrol ether (100 mL) was added and the precipitate was filtered off, washed with diethyl ether and dried *in vacuo*.

Yield: 7.3 g


HPLC (Method 01_B4): $R_t = 7.8$ min

10 LCMS: $m/z = 944$ ($M+H$)⁺

Calculated MW = 943.2

EXAMPLE 5

Preparation of N-terminal extension Boc-His(Boc)-Aib-Glu(O-tBu)-Gly-OSuc



15 A solution of Boc-His(Boc)-Aib-Glu(O-tBu)-Gly-OH (1.0 g, 1.47 mmol) in dry THF (60 mL), was added DIPEA (0.47 g, 3.66 mmol) and *O*-(*N*-succinimidyl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (1.10 g, 3.66 mmol) and the reaction mixture was stirred for 24 h at room temperature. Dichloromethane (250 mL) was added and the solution was washed with H₂O (2 x 100 mL). The
20 organic phase was dried over MgSO₄, filtered and concentrated *in vacuo* to give 1.1 g of Boc-His(Boc)-Aib-Glu(O-tBu)-Gly-OSu.


HPLC (Method 01_B4): $R_t = 8.3$ min

LCMS:m/z = 780.9 (M+H)⁺

Calculated MW = 779.9

5 EXAMPLE 6

Preparation of acylating agent 17-((S)-1-tert-Butoxycarbonyl-3-{2-[2-({2-[2-(2,5-dioxopyrrolidin-1-yloxy)carbonyl]methoxy)ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethylcarbamoyl}propylcarbamoyl)heptadecanoic acid tert-butyl ester



10

The title compound was prepared by the general method for the preparation and activation of acylating agents A-OH A-B-C-D-OH, A-C-D-OH, A-B-C-OH as described above and similar to example 4.

HPLC (Method 01_B4):Rt = 16.2 min


15 LCMS:m/z = 944 (M+H)⁺

Calculated MW = 943.2

EXAMPLE 7

Preparation of acylating agent 17-((S)-1-Carboxy-3-{2-[2-({2-[2-(2,5-dioxo-
pyrrolidin-1-yloxy)carbonyl]methoxy)ethoxy]-ethylcarbamoyl}-methoxy)-
ethoxy]ethylcarbamoyl}propylcarbamoyl)-heptadecanoic acid

20




17-((S)-1-tert-Butoxycarbonyl-3-{2-[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonylmethoxy]ethoxy}ethylcarbamoyl}methoxy)ethoxy]-ethylcarbamoyl}propylcarbamoyl)heptadecanoic acid tert-butyl ester was dissolved in TFA and the resulting solution was stirred for 2 hr. and evaporated *in vacuo* to dryness. The resulting oil was coevaporated with toluene thrice to dryness resulting in an oily residue

LCMS: $m/z = 831 (M+H)^+$

EXAMPLE 8

Preparation of GLP-1 derivative [Arg34]GLP-1-(11-37)-N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamin]ethoxy}ethoxy)acetyl]-[Aib8,Arg34]GLP-1-(7-37)



[Arg34]GLP-1-(11-37) (50 mg, 0.017 mmol) was dissolved in 2 mL water and DIPEA (89 μ L, 0.51 mmol) was added. The mixture was stirred for 10 min before pH was measured to 10.6. Then a solution of 17-((S)-1-tert-butoxycarbonyl-3-{2-[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonylmethoxy]-ethoxy]-ethylcarbamoyl}methoxy)ethoxy]ethylcarbamoyl}propylcarbamoyl)-heptadecanoic acid tert-butyl ester (20.5 mg, 0.022 mmol) in MeCN (1.5 mL) was added dropwise over 10 min. The reaction mixture was stirred for 1 hour before MeCN was removed *in vacuo* and the solution was lyophilized.

The resulting residue was dissolved in NMP (2 mL) whereupon DIPEA (22 μ L, 0.17 mmol) and Boc-His(Boc)-Aib-Glu(OtBu)-Gly-OSu (26 mg, 0.033 mmol) was added. The reaction mixture was stirred for 4 hours before an additional portion of His(Boc)-Aib-Glu(OtBu)-Gly-OSu (13 mg 0.017 mmol) was added and the
5 reaction mixture was stirred over night. Ice cold diethyl ether (20 mL) was added whereupon a white precipitate was formed. The precipitate was isolated by centrifugation and the supernatant was decanted off. The precipitate was washed with 10 mL diethyl ether and dried in the air.

Deprotection

- 10 The crude intermediate was dissolved in TFA-triisopropylsilane-H₂O (95:2.5:2.5, 10 mL) and stirred for 3 h whereupon the solution was concentrated *in vacuo* to app. 1 mL. Ice cold diethyl ether (20 mL) was added whereupon a precipitate was formed. The precipitate was isolated by centrifugation and the supernatant was decanted off. The precipitate was washed with diethyl ether and dried. The
15 crude compound was dissolved in acetic acid-H₂O (3:7) (10 mL) and purified on HPLC.

HPLC (Method 02_B4): Rt = 9.6 min


LCMS:m/z = 1372.5 (M+3H)³⁺

Calculated MW = 4113.7

20

EXAMPLE 9

Preparation of GLP-1 derivative N-epsilon26-[2-(2-[2-(2-[2-(2-[4-(17-tert-butoxycarbonylheptadecanoyl)-amino)-4(S)-tert-butoxycarbonylbutyrylamino]ethoxy)ethoxy]acetyl-amino)ethoxy]ethoxy]acetyl]-
25 [Arg34]GLP-1-(9-37) peptide.



- To a solution of 17-[(S)-1-tert-butoxycarbonyl-3-[2-(2-{[2-(2-carboxymethoxyethoxy)ethylcarbamoyl]methoxy}ethoxy)ethylcarbamoyl]propylcarbamoyl]heptadecanoic acid tert-butyl ester (94.0mg, 0.112mmol) in NMP
- 5 (2.0ml) was added O-(1-succinimidyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (TSTU, 41.7mg, 0.139mmol) and TEA (96.0 μ l, 0.69 mmol). After stirring for 30 min. at room temperature the mixture was added drop wise to a solution of [Arg34]GLP-1-(9-37) peptide (220 mg, 0.069 mmol) in water (9 ml) and TEA (96.0 μ l, 0.69 mmol). After stirring for additional 30
- 10 min at room temperature the mixture was diluted with water (30ml) and lyophilized for 16 h giving an oil/amorphous mixture which was dissolved in a mixture of acetic acid-acetonitrile-water (30:20:50, 180ml), filtered and purified by HPLC to give N-epsilon26-[2-(2-[2-(2-[2-(2-[4-(17-tert-
- 15 butoxycarbonylheptadecanoyl-amino)-4(S)-tert-butoxycarbonylbutyrylamino]ethoxy)ethoxy]acetylaminomethoxy)ethoxy]acetyl]-[Arg34]GLP-1-(9-37) peptide.

HPLC (Method 02_B4_4): Rt = 12.1 min


LCMS:m/z = 1335.5 (M+3H)³⁺

Calculated MW = 4003.6

20

EXAMPLE 10

Preparation of GLP-1 analogue N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]ethoxy}ethoxy)acetylaminomethoxy}ethoxy)-acetyl][Aib8,Arg34]GLP-1-(7-37) peptide.



To a solution of Boc-His(Boc)-Aib-OH (23 mg, 0.052 mmol) in NMP (2.0 ml) were added 2-(1H-9-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 20 mg, 0.052 mmol) and TEA (29 μ l, 0.208 mmol). After stirring for 45 min. the mixture was added to a solution of N-epsilon26-[2-(2-[2-(2-[2-(2-[4-(17-*tert*-butoxycarbonylheptadecanoylamino)-4(*S*)-*tert*-butoxycarbonylbutyrylamino]ethoxy)ethoxy] acetylamino)-ethoxy]ethoxy)acetyl]-[Arg34]GLP-1-(9-37) peptide (83mg, 0.021mmol) and TEA 3.6ul, 0.026mmol). After stirring for 14 days the reaction mixture was diluted with water (100ml) and purified by HPLC. The purified fractions were pooled and the organic solvent removed *in vacuo* before the residue was lyophilized for 16 h.

To the residue was added a mixture of trifluoroacetic-triisopropylsilane-water (94:3:3,10ml). After stirring for 2 hours the reaction mixture was evaporated *in vacuo*, the residue was dissolved in a mixture of water-ammonia (99:1,100ml) and purified by preparative HPLC to give the title compound.

HPLC (Method 02_B4_4): Rt = 9.4 min


LCMS:m/z = 1372 (M+3H)³⁺

Calculated MW = 4113.7

EXAMPLE 11

Preparation of acylating agent 20-[4-((S)-1-*tert*-Butoxycarbonyl-3-{2-[2-(2-(2,5dioxo-pyrrolidin-1-yloxy)carbonyl)ethoxy]-2-(2,5dioxo-pyrrolidin-1-yloxy)carbonyl)ethoxy]acetyl]-[Arg34]GLP-1-(9-37) peptide

ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethylcarbamoyl}-
propylcarbamoyl)piperidin-1-yl]-20-oxo-icosanoic acid tert butyl ester



- 5 The title compound was prepared by the general method for the preparation and activation of acylating agents A-OH A-B-C-D-OH, A-C-D-OH, A-B-C-OH as described above and similar to example 4.

LCMS: $m/z = 1111 (M+H)^+$

- 10 LCMS: $m/z = 1082.6 (M+H)^+$


Calculated MW = 1082.4

15

EXAMPLE 12

Preparation of GLP-1 analogue [Des amino-His7,Glu22,Arg26,34,Lys37(Lys(2-{2-[2-(2-{2-((S)-4-Carboxy-4-{[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}-butyrylamino)ethoxy]-ethoxy}-

- 20 acetylamino)ethoxy]ethoxy}acetyl)]-GLP-1 (7-37) peptide



To a solution of [Glu22,Arg26,34,Lys37]GLP-1-(8-37) peptide (46 mg, 0.013 mmol) in 2 mL water was added DIPEA (50.4 mg, 0.39 mmol) and the mixture was stirred for 10 min before a solution of 20-[4-((S)-1-tert-butoxycarbonyl-3-
 5 {2-[2-({2-[2-(2,5dioxo-pyrrolidin-1-yloxy)carbonylmethoxy]-ethoxy]-ethylcarbamoyl}-methoxy)-ethoxy]-ethylcarbamoyl}-propylcarbamoyl)-piperidin-1-yl]-20-oxo-icosanoic acid tert butyl ester (32.4 mg, 0.03 mmol) in 1 mL MeCN was added dropwise over the course of 15 min. The reaction mixture was stirred for 20 min before water (20 mL) was added, and the solution was
 10 freeze dried

The resulting residue was dissolved in NMP (1 mL) and 4-[2-(2,5-dioxo-pyrrolidin-1-yloxy)carbonyl]-ethyl]-imidazole-1-carboxylic acid adamantan-1-yl ester (Adoc-des amino His-OSu ester) mixture was stirred for 3 hours before it was added drop wise to ice cold diethyl ether (20 mL). The white precipitate was
 15 isolated by centrifugation and washed twice with diethyl ether (20 mL) and dried.

The resulting residue was treated with TFA-TIPS-water (95:2.5:2.5, 1 mL) for 3 hours before it was added drop wise to ice cold diethyl ether (10 mL). The white precipitate was isolated by centrifugation and washed twice with diethyl ether
 20 (10 mL). The residue was purified by preparative HPLC to give the title compound


HPLC (Method 01_B4_2): Rt = 11.1 min

LCMS:m/z = 1484 (M+3H)³⁺

Calculated MW = 4452.1

EXAMPLE 13

Preparation of 4-[2-(2,5-Dioxo-pyrrolidin-1-yloxy-carbonyl)ethyl] imidazole-1-
5 carboxylic acid adamantan-1-yl ester



4-(2-Carboxyethyl) imidazole-1-carboxylic acid adamantan-1-yl ester (1 g, 3.1
10 mmol) was dissolved in THF (5 mL) and DMF (10 mL). The solution was cooled
to 0 °C and TSTU and DIEA were added. The solution was stirred at 0 °C for 1 h,
and at room temperature for 16 h. The sample was concentrated under vacuum.
EtOAc (100 mL) was added, and the solution was washed with 0.2 N HCl (2 x 50
15 mL), dried over MgSO₄, and concentrated under vacuum to yield a sticky
crystalline residue (1.18 g, 90% yield). The crude product was used without
further purification.


LCMS:m/z = 416.2 (M+H)

¹H-NMR (DMSO, 300 MHz) (selected signals) δ 8.22 (s, 1H), 7.37 (s, 1H), 3.02
(t, 2H), 2.82-2.88 (m, 2H), 2.81 (s, 4H), 2.19 (s-br, 9H), 1.66 (s, 6H).

EXAMPLE 14

Preparation of GLP-1 analogue N-epsilon 37{2-[2-(2-{2-[2-((R)-3-carboxy-3-

5 {[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}
propionylamino)ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl [Glu22,
Arg26,34, Lys 37] GLP-1 (8-37) peptide



- 10 The GLP-1 analogue was prepared using a CEM Liberty peptide synthesizer starting with a Fmoc-Lys(Mtt)-wang resin. After the Fmoc group from Ala8 was removed, the N-terminal was protected by performing a double coupling with di-*tert*-butyl dicarbonate. The Mtt group was removed by washing the resin with DCM, treating the resin with hexafluoroisopropanol for 15 min at r.t and washing
- 15 the resin with DCM. The N-epsilon 37 modifications were prepared on the CEM Libert peptide synthesizer using Fmoc-protected reagents and eicosanedioic acid mono-*tert*-butyl ester. The crude peptide was cleaved from the resin TFA-TIPS-Water (95:2.5:2.5) and precipitated in ice cold ether, and isolated by centrifugation. The crude peptide was purified by preparative HPLC (4 cm dia. x
- 20 200 mm, C18, 60 ml/min, 33-53% acetonitrile).

LCMS:m/z = 1065.8 (M+4H)⁴⁺


EXAMPLE 15

Preparation of GLP-1 analogue N-epsilon 37{2-[2-(2-{2-[2-((R)-3-carboxy-3-
 {[1-(19-carboxynonadecanoyl)piperidine-4-
 carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylaminomethoxy]ethoxy}ace-
 tyl [Des amino-His(Adoc)7, Glu22, Arg26,34, Lys 37] GLP-1 (7-37) peptide
 The GLP-1 analogue N-epsilon 37{2-[2-(2-{2-[2-((R)-3-carboxy-3-
 {[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}
 propionylamino)ethoxy]ethoxy}acetylaminomethoxy]ethoxy}acetyl [Glu22,
 Arg26,34, Lys 37] GLP-1 (8-37) peptide (2.1 mg, 0.001 mmol) was dissolved in
 NMP (105 µL). A solution of 4-[2-(2,5-dioxo-pyrrolidin-1-
 yloxycarbonyl)ethyl]imidazole-1-carboxylic acid adamantan-1-yl ester was
 prepared by dissolving 25.3 mg in 1296 µL NMP, and 25 µL of this solution was
 added to the peptide solution followed by DIEA (0.9 µL). The conversion to the
 product was followed by LCMS analysis. After 2 h at r.t, the ELS signal ratio of
 the product to the starting peptide was observed to be 976:28 (97%
 conversion).

LCMS:m/z = 1141.1 (M+4H)⁴⁺

EXAMPLE 16

Preparation of acylating agent 19-{[*trans*-4-((S)-1-Carboxy-3-{2-[2-(2-[2-
 (2,5-dioxo-pyrrolidin-1-yloxycarbonylmethoxy)-ethoxy]-ethylcarbamoyl}-
 methoxy)-ethoxy]-ethylcarbamoyl}-propylcarbamoyl)-cyclohexylmethyl]-
 carbamoyl}-nonadecanoic acid



19-{[*trans*-4-((S)-1-*tert*-Butoxycarbonyl-3-{2-[2-(2-[2-(2,5-dioxo-pyrrolidin-
 1-yloxycarbonylmethoxy)-ethoxy]-ethylcarbamoyl}-methoxy)-ethoxy]-
 ethylcarbamoyl}-propylcarbamoyl)-cyclohexylmethyl]-carbamoyl}-nonadecanoic
 acid *tert*-butyl ester (1.0 g, 0.9 mmol) was stirred in TFA (10 mL) for 1h 45min
 before 100 mL ice cold diethyl ether was added. The white precipitate was

isolated by centrifugation and washed 3 x with diethyl ether to give the title compound.

The precipitate was dried *in vacuo* for 16 hours.


LCMS:m/z = 999 (M+1)⁺

5

EXAMPLE 17

Preparation of GLP-1 analogue N-epsilon37-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-({trans-4-[(19-
carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)-
butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl]-
[DesaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37) peptide

10



[Glu22, Arg26, Arg34, Lys37]GLP-1-(8-37) prepared via recombinant technique
 (300 mg, 0.09 mmol) dissolved in 6 mL water was added DIPEA (373 μ L, 2.19
 mmol) and stirred for 10 min whereupon a solution of 19-{[*trans*-4-((S)-1-
 carboxy-3-{2-[2-({2-[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonylmethoxy)-
 ethoxy]-ethylcarbamoyl}-methoxy)-ethoxy]-ethylcarbamoyl}-propylcarbamoyl)-
 cyclohexylmethyl]-carbamoyl}-nonadecanoic acid (175.7 mg, 0.18 mmol) in
 NMP (1.7 mL) was added dropwise. The mixture was stirred for 90 min before
 Na₂HPO₄·7H₂O (470.6 mg, 1.76 mmol) was added and pH was adjusted to 8.4
 using 1 N HCl.

15

20

In another flask 3-(1H-Imidazol-4-yl)-propionic acid (93.2 mg, 0.53 mmol), *O*-
 (*N*-succinimidyl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (159.0 mg,
 0.53 mmol) and DIPEA (180 μ L, 1.06 mmol) was mixed in NMP (0.75 mL) and
 the solution was stirred for 1 hour before it was added drop wise to the reaction

25


mixture containing the peptide. The mixture was stirred for 14 hours whereupon piperidine (350 μ L, 3.51 mmol) was added. The mixture was stirred for another two hours, before it was diluted with water to a total volume of 20 mL, and purified by preparative HPLC, using a gradient from 33 to 53% MeCN in water.

5 LCMS:m/z = 1475.8 (M+3H)³⁺

EXAMPLE 18

Alternative preparation of GLP-1 analogue N-epsilon26-[2-(2-{2-[2-(2-{(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)-acetylamin

10 yl]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)



[Arg34]GLP-1-(11-37) prepared via recombinant technique (100 mg, 0.033 mmol) dissolved in 2 mL water was added DIPEA (113 μ L, 0.66 mmol) and stirred for 10 min whereupon 17-((S)-1-carboxy-3-{2-[2-({2-[2-(2,5-dioxo-
15 pyrrolidin-1-yloxycarbonyl-methoxy)-ethoxy]-ethylcarbamoyl}-methoxy)-ethoxy]-ethylcarbamoyl}-propyl-carbamoyl)-heptadecanoic acid (55 mg, 0.066 mmol) (Prepared in accordance with example 2,3 and 13) was added in small portions over 15 min. The mixture was stirred for 60 min before Na₂HPO₄·7H₂O (353.9 mg, 1.32 mmol) was added and pH was adjusted to 8.3 using 1 N HCl.

20 Fmoc-His-Aib-Glu-Gly-OSu (246.2 mg, 0.33 mmol) was added to the reaction mixture containing the peptide and the mixture was stirred for 14 hours whereupon piperidine (400 μ L, 4.05 mmol) was added. The mixture was stirred for another 30 min, before it was diluted with water-MeCN (9:1) to a total volume of 40 mL, and purified by preparative HPLC, using a gradient from 30 to
25 50% MeCN in water.

LCMS:m/z = 1372.5 (M+3H)³⁺

EXAMPLE 19

Alternative preparation of GLP-1 analogue N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)-acetylaminol]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37) peptide

Acylation: Recombinant [Arg34]GLP-1-(11-37) (99 mg; 33 µmol) was suspended in H₂O (4 mL) in the 70 mL reaction chamber of a Metrohm 848 Titrino plus titrator. The pH was adjusted to pH=11.3 controlled by the autotitrators SET program (by addition of 3.8 mL, 0.1 M NaOH (aq)). At pH = 11.3 the peptide was fully dissolved. The activated sidechain 17-((S)-1-Carboxy-3-{2-[2-({2-[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonylmethoxy)ethoxy]-ethylcarbamoyl}-methoxy)-ethoxy]ethylcarbamoyl}propylcarbamoyl)-heptadecanoic acid (55 mg, 66 µmol, 2 eq) was dissolved in NMP (250 µL) and transferred to a 250 µL Hamilton syringe. By the action of an automated syringe pump 250 µL (2.0 eq) of this solution was added over 10 minutes. After additional 60 minutes a sample (10 µL) was taken out, diluted by 90 µL MeCN-H₂O (1:1) UPLC showed a major peak of N26 acylated product (appr. 95%)+ trace of unreacted peptide + trace of hydrolysed side chain.

Ligation: Tetrapeptide NHS ester Fmoc-His-Aib-Glu-Gly-OSu (123 mg, 165 µmol, 5 eq) was dissolved in NMP (250 µL). The pH of the reaction mixture was adjusted to 6.9 with dilute acetic acid. Then pH was adjusted to 7.0 by the pH-stat function on the titrator. The 250 µL of NHS ester was added over 20 minutes. The pH was stabilized on pH=7.0 ± 0.1.

Sample taken out after additional 30 min and UPLC showed a 1:1 ratio of the acylated intermediate and the expected product (with Fmoc protection in the N-terminal position).

Another 5 eq of the tetrapeptide NHS ester was added as above. The solution was left stirring for 16 h. The ratio was now 2:8 of the acylated intermediate and the product.

Another 2.5 eq (Total of 12.5 eq) of the tetrapeptide NHS ester was added as above. The solution was left stirring for 16 h. Ratio was now approx. 1:9 of the acylated intermediate and the product.


Piperidine (1.6 mL) was added to the reaction mixture and stirring continued for 5 1h.

UPLC showed full deprotection. The crude product was purified on reverse phase HPLC to yield 62 mg (45 %) of the wanted product (98% pure).

LCMS:m/z = 1372.5 (M+3H)³⁺

10 EXAMPLE 20

Preparation of Fmoc-His(Boc)-Aib-Glu(O-tBu)-Gly-OH



15

	Name	Dens	Mw	Mol	n	W	V	

		[g/ml]	[g/mol]	Ratio	[mmol]	[g]	ml	
	Product: C ₄₁ H ₅₂ N ₆ O ₁₁		804.905	1	98	78.9		
1 st AA	2-chlorotriylchloride resin 1% DVB			1	98	140		
	Fmoc-Gly-OH		297.3	2	196	58.3		
	DIPEA	0.76	129.3	2	196		66.7	pH 9
	Subst. Fmoc-Gly-resin: 0.7 mmol/g							
2 nd AA	Fmoc-Glu(OtBu)-OH		425.5	2	196	86.9		
	TCTU		355.5	2	196	69.7		
	DIPEA	0.76	129.3	2	196		66.7	
	Fmoc-Glu(OtBu)-OH		425.5	0.5	49	21.7		Re- coupling
	TCTU		355.5	0.5	49	17.4		
	DIPEA	0.76	129.3	0.5	49		17.6	
3 th AA	Fmoc-Alb-OH		325.4	2	196	63.8		
	TCTU		355.5	2	196	69.7		
	DIPEA	0.76	129.3	2	196		66.7	

4 th AA	Fmoc-His(boc)-OH		477.5	2	196	93.6		
	TCTU		355.5	2	196	69.7		
	DIPEA	0.76	129.3	2	196		66.7	

Loading of Glycine

The resin was pre-swelled in DCM (1 liter, 20 min) before it was added a solution of Fmoc-Gly-OH and DIPEA in 500 mL DCM, and agitated for 60 min. The resin
 5 was washed with DMF (2 x 500 mL) and 2 x 500 mL DCM-MeOH-DIPEA (80:15:5, 10 min) then DMF (3 x 500 mL), DCM (500mL) and left overnight at RT.

Coupling 1

20% piperidine in DMF (500 mL) for 50 min. was used for Fmoc deprotection,
 10 then the resin was washed with DMF (8 x 500 mL).

Fmoc-Glu(OtBu)-OH and TCTU were dissolved in 700 mL DMF added to reactor and DIPEA was added. The mixture was stirred for 6 h. According HPLC test free amine groups was still present; coupling was repeated using ¼ of reagents. When coupling reaction was finished (no amino groups present), resin was
 15 washed with DMF (4 x 500mL)

Coupling 2

Fmoc-Aib-OH and TCTU were dissolved in 700 mL DMF solution, put into the reactor and DIPEA was added. The mixture was stirred for 50 min. When coupling reaction was finished (no amino groups present), resin was washed
 20 with DMF (4 x 500mL).

Coupling 3

20% piperidine in DMF (500 mL) for 30 min was used for Fmoc deprotection, and then the resin was washed with DMF (8 x 500 mL).

Fmoc-His(Boc)-OH and TCTU were dissolved in 700 mL DMF, solution put into the reactor and DIPEA was added. The mixture was stirred for 50 min. When coupling reaction was finished (no amino groups present), resin was washed with DMF (3 x 500mL) and DCM (2 x 500mL).

5 **1st Cleavage**

The 1st cleavage was done using 1/7 of resin. Trifluoroethanol-DCM (1:4, 500 mL) was added and the resin was agitated for 70 min. The filtrate was collected and the solvent was removed in vacuum to give oil. The oil was dissolved in ethyl acetate and left stay in refrigerator to form crystals. Crystals were
10 filtrated, washed using diethyl ether and dried on air, to give 6,1 g of product (yield 45%), purity by HPLC 99,0%.

2nd Cleavage

The 2nd cleavage was done using 3/7 of resin. Trifluoroethanol-DCM (1:4, 1000 mL) was added and the resin was agitated for 90 min. The filtrate was collected
15 and the solvent was removed in vacuum to give oil. The oil was dissolved in ethyl acetate and left stay in refrigerator overnight to form crystals. Crystals were filtrated, washed by diethyl ether and dried on air, to give 33,1 g of product (yield 80%), purity by HPLC 98,7%.

Yield: 6,1g (45 %)

20 **ESI+MS** m/z: 805.1 (M+H)⁺, 1610.7 (2M+H)⁺.


HPLC R_t (Luna 4.6 x 250, 5ul, 100A; acetonitrile / buffer* 30:70 to 60:40, 30 min, 1 ml/min., 220nm): 23.31 min.; **purity 99.0%**

and 33,1 g (80 %)

25 **ESI+MS** m/z: 805.1 (M+H)⁺, 1610.8 (2M+H)⁺.

HPLC R_t (Luna 4.6 x 250, 5ul, 100A, acetonitrile / buffer* 30:70 to 60:40, 30 min, 1 ml/min., 220nm): 23.16 min.; **purity 98.7%**

*buffer: 2.71g KH₂PO₄, 7.13g NaH₂PO₄.2H₂O dissolved in H₂O (2L);

EXAMPLE 21**Preparation of Fmoc-His-Aib-Glu-Gly-OSuc . TFA salt**

Fmoc-His(Boc)-Aib-Glu(O-tBu)-Gly-OH (1.25 g, 1.56 mmol) was dissolved in THF (10 mL) and were added DIPEA (0.64 g, 3.73 mmol) and TSTU (0.56 g, 1.87 mmol, 1.2 eq). The mixture was stirred over night.

LCMS: app. 95% conversion. The mixture was filtered and the solvent was removed *in vacuo*. EtOAc (100 mL) was added and the organic phase was washed twice with cold 0.1 N HCl and dried over Na₂SO₄, filtered and

evaporated to give crude Fmoc-His(Boc)-Aib-Glu(OtBu)-Gly-OSu (1.1 g, 79 %).


The crude product was dissolved in DCM (2 mL) and added TFA (1mL). Stirred for 1h. LCMS: 100% deprotected. After evaporation of the organic solvent ice-cold diethylether was added to the residue and the resulting precipitate was

collected by filtration and dried in a vacuum oven to give Fmoc-His-Aib-Glu-Gly-OSu (430 mg)

LCMS: $m/z = 746.3$ (M+H)⁺

EXAMPLE 22

Preparation of 3-(1-trityl-1H-imidazol-4-yl)-propionic acid 2,5-dioxo-pyrrolidin-1-yl ester




3-(*N*-Tritylimidazol-4-yl)propionic acid (Jung et al., Bioorg. Med. Chem. Lett., 6, 2317-2336, 1998) (50g, 0.13 mol) was dissolved in DCM (500 ml), *N*-hydroxysuccinimide (24 g, 0.209 mol) and *N,N'*-dicyclohexylcarbodiimide (35 g 0.170 mol) was added, while maintaining the internal temperature below 30°C with an icebath. The resulting mixture was stirred at room temperature overnight. The mixture was filtered and the resulting solution was concentrated *in vacuo*, re-dissolved in THF (350 ml) upon heating and mixed with 2-propanol (350ml) to a resulting temperature of 32 °C, then cooled to 5 °C. The crystalline product was filtered and washed with 2-propanol (150 ml) and dried in vacuum to afford the title compound (47.3 g, yield 75%).

¹H NMR (*D*₆-DMSO, 400MHz): δ 7.15-6.99 (m, 9H), 6.82 (s, 1H), 6.81-6.62 (m, 6H), 6.38 (s, 1H), 2.63 (t, 3H), 2.4 (m, 6H).

EXAMPLE 23

Preparation of 4-[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-ethyl]-1*H*-imidazol-1-ium trifluoroacetate




3-(1-Trityl-1*H*-imidazol-4-yl)-propionic acid 2,5-dioxo-pyrrolidin-1-yl ester (40g, 83 mmol) was dissolved in DCM (240 ml). Triisopropylsilane (42 ml) and trifluoroacetic acid (240 ml) was added and the resulting solution was stirred at room temperature for 90 min. The solution was evaporated *in vacuo*, redissolved in acetonitrile (120 ml), and tert-butylmethyl ether (290 ml) was added

dropwise and the solution was cooled to 8 °C. The precipitate was collected by filtration and dried in vacuum to afford a white compound (24 g, 82%).

¹H NMR (*D*₆-DMSO, 400MHz): δ 8.90 (s, 1H), 7.47 (s, 1H), 3.09 (t, 2H), 2.79 (t, 2H), 2.79 (s, 4H).

EXAMPLE 24

Alternative preparation of GLP-1 analogue N-epsilon37-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)-butyrylamino]ethoxy}ethoxy)acetylaminomethyl]ethoxy}ethoxy)acetyl]-[DesaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37) peptide



[Glu22,Arg26,Arg34,Lys37]GLP-1-(8-37) peptide (80 g, 0.023 mol) prepared via recombinant technique was dissolved in water (6400 ml) and triethylamine (28 ml) was added to pH 11.0. (22S)-22-{[(trans-4-[(19-carboxynonadecanoyl)amino]methyl)-cyclohexyl]carbonyl}amino-1-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,10,19-trioxo-3,6,12,15-tetraoxa-9,18-diazatricosan-23-oic acid (34.9 g, 0.035 mol) was dissolved in NMP (210 ml) and added to the solution over 2 hr., while maintaining the pH between 11.0 – 11.1 by continuous addition of triethylamine. The pH was adjusted to 7.0 by addition of 1M sulphuric acid (aq, 140 ml). 4-[2-(2,5-Dioxo-pyrrolidin-1-yloxy)carbonyl]-ethyl-1H-imidazol-1-ium trifluoroacetate (36.99 g, 0.105 mol) was dissolved in NMP and added to the solution over 2 hr. while maintaining the pH at 7.0 – 7.1 by continuously addition of triethylamine.. The pH was adjusted to 11.2 by addition of 1 M NaOH (aq, 500 ml) and the solution was stirred at room temperature for


7 hr. pH was adjusted to 7.4 by addition of 1M sulphuric acid (aq, 140 ml), to a total of 7973.8 g which was purified by preparative HPLC.

LCMS: $m/z = 1476 (M+3H)^{3+}$

5

EXAMPLE 25

Preparation of [Aib8,Arg34]GLP-1-(7-37) peptide



10

Arg34-GLP-1[9-37] • 4TFA (103 mg; 0.028 mmol) was dissolved in 2 mL water and transferred to a titrator reaction chamber with additional 2 x 1 mL water. The reaction chamber was equipped with a stirring magnet, pH electrode and a titrant tube. The pH of the solution was 1.9. The titrator was programmed to a 'STAT' method at fixed pH = 11.3. The titrant, sodium hydroxide (3.27 mL, 0.1 M aq), was added by the titrator to reach pH = 11.3. $(\text{Boc})_2\text{O}$ (186 mg, 0.85 mmol, 3 eq) was dissolved in NMP (2.500 mL) and a 250 μL Hamilton syringe

15

was filled with this solution (i.e. 250 μ L; 18.6 mg (Boc)₂O, 3 eq).

Water (1.0 mL) was added to the reaction chamber to make a total volume of 8.3 mL and the (Boc)₂O NMP solution was then added over 20 min by aid of a syringe pump at room temperature. The titrator was keeping the pH = 11.3 by
5 automatic addition of the titrant. After stirring for additional 10 minutes LCMS showed 88 % of the Lys26(NHBoc) product together with a diboc product (9%) and starting material (3%). The pH of the solution was adjusted to 6.5 with a small volume of dilute HOAc (aq) and the titrator was set at pH = 7.5 for the further reaction.


- 10 A solution of Boc-His(Boc)-Aib-OSu (305 mg, 0.568 mmol, 20 eq) was dissolved in NMP (500 μ L) giving a total volume of 715 μ L. Of this solution 2 x 250 μ L (2 x 7 eq) was added to the reaction mixture over 2 x 30 minutes keeping pH = 7.5. Immediate precipitation of the Boc-His(Boc)-Aib-OSu was observed, but upon stirring all dissolved. After end of addition the mixture was stirred for another
15 2 h at pH = 7.5 and at room temperature to allow dissolution and reaction of the reactant.

The mixture was lyophilized and treated with TFA containing 3% TIPS and 3% water for 2 h. The solvents were evaporated and the residue was purified by HPLC to give the desired product.

- 20 LCMS m/z: 849.88 (M+4H)⁴⁺, 1132.86 (M+3H)³⁺. Calcd. 3396.698 (M+H)⁺.

EXAMPLE 26

Preparation of Boc-His(Boc)-Aib-OH



Loading of Aib: 2-Chlorotriylchloride resin 1% DVB (Load 1.1 mmol/g) (10.0 g, 11 mmol) was pre-swelled in DCM before it was added a solution of Fmoc-Aib-OH (7.16 g, 22 mmol) and DIPEA (9.4 mL, 55 mmol) in DCM (100 mL). The mixture was agitated for 60 min. The resin was washed with NMP (2 x 100 mL) and DCM-MeOH-DIPEA (80:15:5) (2 x 100 mL, 10 minutes each), and NMP (3 x 100 mL). The washed resin was treated with 20% piperidine in NMP (3 x 100 mL, 10 min each). The resin was washed with NMP (6 x 100 mL).


Coupling : Boc-His(Boc)-OH (15.64 g, 44 mmol) was dissolved in NMP (100 mL) and DCM (20 mL) and HOBt (5.95 g, 44 mmol) was added followed by slow addition of DIC (6.81 mL, 44 mmol). The mixture was stirred for 15 min before DIPEA (9.40 mL, 55 mmol) was added. The activated mixture was added to the resin and the resin was agitated for 16h before it was washed with NMP (4 x 100 mL) and DCM (10 x 100mL).

Cleavage: Trifluoroethanol-DCM (1:4, 100 mL) was added and the resin was agitated for 1 hour. The filtrate was collected and a new portion of trifluoroethanol-DCM (1:4, 100 mL) was added and agitated for 15 min and the filtrate was collected. The combined filtrates were evaporated *in vacuo* and petrolether (50 mL) was added. The resulting precipitate was washed with petrolether, collected and dried in vacuum oven for 16 h at 40 °C to give Boc-His(Boc)-Aib-OH (1.00 g, yield 21 %, purity 95%).

LCMS m/z: 441.18 (M+H)⁺. Calcd. 440.227 (M+H)⁺.

EXAMPLE 27

Preparation of Boc-His(Boc)-Aib-OSu




- Boc-His(Boc)-Aib-OH (0.70 g, 1.59 mmol) was dissolved in THF (5.0 mL) and TSTU (1.44 g, 4.77 mmol) and DIPEA (1.36 mL, 7.95 mmol) was added. The reaction mixture was stirred at rt. for 2 h. LCMS showed almost complete conversion into the oxazolone product. The reaction mixture was filtered and the solvent was evaporated. The residue was re-dissolved in DCM (10 mL) and N-hydroxysuccinimide (292 mg, 2.56 mmol, 1.6 eq) was added. The mixture was stirred over night at room temperature. UPLC show a major peak of the desired Su-ester (85%), trace of un-reacted starting material and 5% of the ring-closed oxazolone. The solvent was evaporated at room temperature under reduced pressure and H₂O (25 mL) was added to dissolve unreacted N-hydroxysuccinimide. The H₂O was decanted off and the residue was dissolved in EtOAc (100 mL) dried over MgSO₄, filtered and evaporated to give a white foam containing 70% of the desired product.

LCMS m/z: 538.18 (M+H)⁺. Calcd. 538.251 (M+H)⁺

EXAMPLE 28

Preparation of Fmoc-His-Aib-OSu




Fmoc-His(Trt)-Aib-OH (5g, 7.1 mmol) was dissolved in THF (50ml). DCC (1.61g, 7.8 mmol) and NHS (0.94g, 8.2 mmol) was added and the resulting solution was stirred for 16hr at room temperature. The DCU was filtered and the solution was evaporated *in vacuo*. The resulting oil was dissolved in DCM (34ml) and

trifluoroacetic acid (34ml) and TIPS (6ml) was added. The solution was stirred for 2 hr at room temperature, evaporated *in vacuo* to 25 ml, added dropwise to TBME (200 ml), stirred for 60 min, and the resulting white precipitate is collected by filtration, and washed with additional TBME. The collected
 5 precipitate was dried in vacuum for 16 hr.

LCMS : $m/z = 560 (M+H)^+$

EXAMPLE 29

Preparation of GLP-1 derivative [Aib8,Arg34]GLP-1-(7-37) peptide



- 10 [Arg34] GLP-1(9-37) peptide • 4TFA (103 mg; 0.028 mmol) was dissolved in 0.1 M TEA(aq., 7.5ml) additional TEA was added (140μl) to a resulting pH of 11.28. FmocOSu (90mg) was dissolved in NMP (1600 μl) and 334μl (0.055 mmol) of this solution was added dropwise to the aqueous peptide solution. pH was adjusted to 7 by addition of 1M H₂SO₄(aq). FmocHisAibOSu trifluoroacetate salt
 15 (90mg, 0.134 mmol) was dissolved in NMP (800μl) and added dropwise to the solution while maintaining the pH between 7.0 and 7.5 by continuous addition of 1M NaOH(aq). Piperidin (2ml) was added and the resulting solution was stirred for 60 min. at room temperature. TBME (5 ml) was added and the mixture was stirred for 30 min. The aqueous phase was separated and lyophilised.
- 20 LCMS: $m/z = 1134 (M+3H)^{3+}$

CLAIMS

1. A method for making a GLP-1 analogue or derivative comprising one or more non-proteogenic amino acids in the N-terminal part, said method comprising the steps of:

- 5 i) culturing a host cell comprising a nucleotide sequence encoding a precursor molecule of said GLP-1 analogue under suitable conditions for expression of said precursor molecule,
ii) separating the expressed precursor molecule from the culture broth,
iii) coupling an N-terminal amino acid extension comprising one or more non-
10 proteogenic amino acids to the expressed precursor molecule,
iv) isolating the resulting GLP-1 analogue or derivative by suitable means.

2. A method according to claim 1 wherein the lysine group(s) of the precursor molecule are protected after step ii) and deprotected again after coupling of the N-terminal extension.

- 15 3. A method according to claim 1 wherein the N-terminal amino acid extension is protected before its use in step iii) and deprotected again after coupling of the N-terminal extension.

4. A method according to any one of claims 1-3, wherein the precursor molecule of said GLP-1 analogue is selected from the list of precursor molecules
20 comprising the amino acid sequence of the general formula:

Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-Ala-Xaa₂₅-
Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-Xaa₃₈-Xaa₃₉-
Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅

wherein

- 25 Xaa₁₆ is Val or Leu;
Xaa₁₈ is Ser, Lys or Arg;
Xaa₁₉ is Tyr or Gln;
Xaa₂₀ is Leu or Met;

- Xaa₂₂ is Gly or Glu;
 Xaa₂₃ is Gln, Glu, Lys or Arg;
 Xaa₂₅ is Ala or Val;
 Xaa₂₆ is Lys, Glu or Arg;
 5 Xaa₂₇ is Glu or Leu;
 Xaa₃₀ is Ala, Glu or Arg;
 Xaa₃₃ is Val, Lys or Arg;
 Xaa₃₄ is Lys, Glu, Asn, His or Arg;
 Xaa₃₅ is Gly;
 10 Xaa₃₆ is Arg, Gly or Lys;
 Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;
 Xaa₃₈ is Lys, Ser, or is absent.
 Xaa₃₉ is Ser, Lys, or is absent;
 Xaa₄₀ is Gly, or is absent;
 15 Xaa₄₁ is Ala, or is absent;
 Xaa₄₂ is Pro, or is absent;
 Xaa₄₃ is Pro, or is absent;
 Xaa₄₄ is Pro, or is absent;
 Xaa₄₅ is Ser, or is absent;
 20 provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent
 then each amino acid residue downstream is also absent.

5. A method according to any one of claims 1-3, wherein the precursor molecule of said GLP-1 analogue is selected from the list of precursor molecules comprising the amino acid sequence of the general formula:

- 25 Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-Xaa₂₃-
 Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-Xaa₃₇-
 Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅

wherein

- Xaa₉ is Glu or Asp
 30 Xaa₁₀ is Gly or Ala
 Xaa₁₆ is Val or Leu;

- Xaa₁₈ is Ser, Lys or Arg;
 Xaa₁₉ is Tyr or Gln;
 Xaa₂₀ is Leu or Met;
 Xaa₂₂ is Gly or Glu;
 5 Xaa₂₃ is Gln, Glu, Lys or Arg;
 Xaa₂₅ is Ala or Val;
 Xaa₂₆ is Lys, Glu or Arg;
 Xaa₂₇ is Glu or Leu;
 Xaa₃₀ is Ala, Glu or Arg;
 10 Xaa₃₃ is Val, Lys or Arg;
 Xaa₃₄ is Lys, Glu, Asn, His or Arg;
 Xaa₃₅ is Gly;
 Xaa₃₆ is Arg, Gly or Lys;
 Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;
 15 Xaa₃₈ is Lys, Ser, or is absent.
 Xaa₃₉ is Ser, Lys, or is absent;
 Xaa₄₀ is Gly, or is absent;
 Xaa₄₁ is Ala, or is absent;
 Xaa₄₂ is Pro, or is absent;
 20 Xaa₄₃ is Pro, or is absent;
 Xaa₄₄ is Pro, or is absent;
 Xaa₄₅ is Ser, or is absent;
 provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent
 then each amino acid residue downstream is also absent.

- 25 6. A method according to any one of claims 1-3, wherein the precursor molecule
 of said GLP-1 analogue is selected from the list of precursor molecules
 comprising the amino acid sequence of the general formula:

Xaa₈- Xaa₉- Xaa₁₀-Thr-Phe-Thr-Ser-Asp-Xaa₁₆-Ser-Xaa₁₈-Xaa₁₉-Xaa₂₀-Glu-Xaa₂₂-
 Xaa₂₃-Ala-Xaa₂₅-Xaa₂₆-Xaa₂₇-Phe-Ile-Xaa₃₀-Trp-Leu-Xaa₃₃-Xaa₃₄-Xaa₃₅-Xaa₃₆-
 30 Xaa₃₇-Xaa₃₈-Xaa₃₉-Xaa₄₀-Xaa₄₁-Xaa₄₂-Xaa₄₃-Xaa₄₄-Xaa₄₅

wherein

Xaa₈ is Ala, Gly, Val, Leu, Ile, Lys

Xaa₉ is Glu, Asp

Xaa₁₀ is Gly, Ala

Xaa₁₆ is Val or Leu;

5 Xaa₁₈ is Ser, Lys or Arg;

Xaa₁₉ is Tyr or Gln;

Xaa₂₀ is Leu or Met;

Xaa₂₂ is Gly or Glu;

Xaa₂₃ is Gln, Glu, Lys or Arg;

10 Xaa₂₅ is Ala or Val;

Xaa₂₆ is Lys, Glu or Arg;

Xaa₂₇ is Glu or Leu;

Xaa₃₀ is Ala, Glu or Arg;

Xaa₃₃ is Val, Lys or Arg;

15 Xaa₃₄ is Lys, Glu, Asn, His or Arg;

Xaa₃₅ is Gly;

Xaa₃₆ is Arg, Gly or Lys;

Xaa₃₇ is Gly, Ala, Glu, Pro, Lys, or is absent;

Xaa₃₈ is Lys, Ser, or is absent.

20 Xaa₃₉ is Ser, Lys, or is absent;

Xaa₄₀ is Gly, or is absent;

Xaa₄₁ is Ala, or is absent;

Xaa₄₂ is Pro, or is absent;

Xaa₄₃ is Pro, or is absent;

25 Xaa₄₄ is Pro, or is absent;

Xaa₄₅ is Ser, or is absent;

provided that if Xaa₃₈, Xaa₃₉, Xaa₄₀, Xaa₄₁, Xaa₄₂, Xaa₄₃, Xaa₄₄ or Xaa₄₅ is absent then each amino acid residue downstream is also absent.

7. A method according to any one of claims 1-6, wherein the non-proteogenic amino acids in the N-terminal amino acid extension comprising one or more
30 non-proteogenic amino acids, are selected from the group consisting of γ -carboxyglutamate, ornithine, phosphoserine, D-amino acids such as D-alanine

and D-glutamine, D-alanine and D-leucine, Aib (α -aminoisobutyric acid), Abu (α -aminobutyric acid), Tle (tert-butylglycine), 3-aminomethyl benzoic acid, anthranilic acid, des-amino-Histidine, β -alanine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N α -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine, 4-pyridylalanine, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, (1-aminocyclooctyl) carboxylic acid, α -methyl prolin, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine.

8. A method according to any one of claims 1-7, wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

Xaa₇-Xaa₈- Xaa₉- Xaa₁₀
wherein

Xaa₇ is selected from L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N α -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine, 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine

Xaa₈ is selected from Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid and alpha-methyl proline

Xaa₉ is selected from Glu, Asp, γ,γ -dimethyl Glu, β,β -dimethyl Glu and β,β -dimethyl Asp, and

Xaa₁₀ is selected from Gly, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-

aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, and (1-aminocyclooctyl) carboxylic acid.

9. A method according to any one of claims 1-7, wherein the N-terminal amino acid extension comprising one or more non-proteogenic amino acids has the general formula

Xaa₇-Xaa₈

wherein

Xaa₇ is selected from L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N ^{α} -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine; 1-methyl histidine, 3-methyl histidine, 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine; and

Xaa₈ is selected from Gly, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid and alpha-methyl proline

10. A method according to any one of claims 1-7, wherein the N-terminal amino acid extension comprising one non-proteogenic amino acid with the general formula

Xaa₇

wherein

Xaa₇ is selected from D-histidine, desamino-histidine, 2-amino-histidine, β -hydroxy-histidine, homohistidine, N ^{α} -acetyl-histidine, α -fluoromethyl-histidine, α -methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine; 1-methyl histidine, 3-methyl histidine, and 4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid β -(1,2,4-triazol-1-yl)-alanine.

11. A method according to claim 10, wherein the N-terminal amino acid extension is desamino-histidine and the coupling reaction is carried out by a 4-

[2-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-ethyl]-1*H*-imidazol-1-ium salt, e.g. the salt trifluoroacetate, with the expressed precursor molecule.


12. A method according to any one of claims 1-11, further comprising the step of acylating the epsilon-amino-group of at least one lysine residue in the expressed precursor molecule with an acylating agent, which is optionally activated and/or protected with one or more protection group(s).

13. A method according to claim 12, wherein the acylating agent is a carboxylic acid analogue of the general formula:

A-OH, A-C-D-OH, A-B-C-OH or A-B-C-D-OH

which is optionally activated and/or protected with one or more protection group(s),
wherein,


A is selected from the group consisting of;



wherein n is selected from the group consisting of 14, 15, 16 17, 18 and 19, p is selected from the group consisting of 10, 11, 12, 13 and 14, and d is selected from the group consisting of 0, 1, 2, 3, 4 and 5, and m is selected from the group consisting of 11, 12, 13, 14, 15, 16, 17, k is selected from the group consisting of 0, 1, 2, 3, 4, 5, 11 and 27, and m is selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6, and R1 is a generally accepted protection group.


group.

B is selected from the group consisting of



- 5 wherein x is selected from the group consisting of 0, 1, 2, 3 and 4, and y is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12,


C is selected from the group consisting of




- 10 wherein b and e are each independently selected from the group consisting of 0, 1 and 2, and c and f are each independently selected from the group consisting of 0, 1 and 2 with the proviso that b is 1 or 2 when c is 0, or b is 0 when c is 1 or 2, and e is 1 or 2 when f is 0, or e is 0 when f is 1 or 2, wherein, when one or more free carboxylic acid(s) are present, they are optionally protected with a generally accepted protection group and

15

D is selected from the group consisting of





and wherein k is selected from the group consisting of 0, 1, 2, 3, 4, 5, 11 and 27, and m is selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6.

14. A method according to claim 13, wherein R1 is selected from the group consisting of 9H-fluoren-9-ylmethoxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc), Benzylcarbamate (Cbz).

15. A method according to any one of claims 1-14, wherein the host cell is selected from a mammalian host cell, an avian host cell, an insect host cell, a plant host cell, a bacterial host cell, a fungal host cell and a yeast host cell.




Fig. 1

2/15

a)

NcoI
~~~~~

GlyThrSerMet AlaLysArg **ThrPheThr SerAspValSer SerTyrLeu GluGlyGln**  
 1 GGTACCTCCA TGGCTAAAAG AACTTTTACT TCTGATGTTT CTTCTTATTT GGAAGGTCAA  
 CCATGGAGGT ACCGATTTTC TTGAAAATGA AGACTACAAA GAAGAATAAA CCTTCCAGTT  
XbaI  
~~~~~

AlaAlaLysGlu PheIleAla TrpLeuVal ArgGlyArgGly ***
 61 GCTGCTAAAG AATTTATTGC TTGGTTGGTT AGAGGTAGAG GTTAGATCTA GAGATCAT
 CGACGATTTT TTAATAACG AACCAACCAA TCTCCATCTC CAATCTAGAT CTCTAGTA

b)

NcoI
~~~~~

GlyThrSerMet AlaLysArg **GluGluAla GluLysAlaGlu GlyThrPhe ThrSerAsp**  
 1 GGTACCTCCA TGGCTAAAAG AGAAGAAGCT GAAAAGGCTG AAGGTACTTT TACTTCTGAT  
 CCATGGAGGT ACCGATTTTC TCTTCTTCGA CTTTCCGAC TTCCATGAAA ATGAAGACTA

**ValSerSerTyr LeuGluGlu GlnAlaAla ArgGluPheIle AlaTrpLeu ValArgGly**  
 61 GTTTCTTCTT ATTTGGAAGA ACAAGCTGCT AGAGAATTTA TTGCTTGGTT GGTTAGAGGT  
 CAAAGAAGAA TAAACCTTCT TGTTCGACGA TCTCTTAAAT AACGAACCAA CCAATCTCCA  
XbaI  
~~~~~

ArgGlyLysGlu AlaGlu***
 121 AGAGGTAAAG AAGCTGAATA GAATCTAGAG ATCAT
 TCTCCATTTT TTCGACTTAT CTTAGATCTC TAGTA

c)

NcoI
~~~~~

GlyThrSerMet AlaLysArg **GluGluAla GluLysAlaGlu GlyThrPhe ThrSerAsp**  
 1 GGTACCTCCA TGGCTAAAAG AGAAGAAGCT GAAAAGGCTG AAGGTACTTT TACTTCTGAT  
 CCATGGAGGT ACCGATTTTC TCTTCTTCGA CTTTCCGAC TTCCATGAAA ATGAAGACTA

**ValSerSerTyr LeuGluGlu GlnAlaAla ArgGluPheIle AlaTrpLeu ValArgGly**  
 61 GTTTCTTCTT ATTTGGAAGA ACAAGCTGCT AGAGAATTTA TTGCTTGGTT GGTTAGAGGT  
 CAAAGAAGAA TAAACCTTCT TGTTCGACGA TCTCTTAAAT AACGAACCAA CCAATCTCCA  
XbaI  
~~~~~

ArgLysGluAla Glu***
 121 AGAAAAGAAG CTGAATAGAA TCTAGAGATC AT
 TCTTTTCTTC GACTTATCTT AGATCTCTAG TA

Fig. 2 a)-c)

3/15

d)

NcoI

~~~~~

GlyValSerMet AlaLysArg **GluGlyThr PheThrSerAsp ValSerSer TyrLeuGlu**

1 GGGGTATCCA TGGCTAAGAG AGAAGGTACC TTCACCTCTG ACGTCTCGAG TTA~~CT~~TGGAA

CCCCATAGGT ACCGATTCTC TCTTCCATGG AAGTGGAGAC TGCAGAGCTC AATGAACCTT

**GlyGlnAlaAla LysGluPhe IleAlaTrp LeuValArgGly ArgGly\*\*\***

61 GGCCAAGCTG CTAAGGAGTT CATCGCTTGG TTGGTTAGAG GCCGCGGTTA GACGCAGCCC

CCGGTTCGAC GATTCTCTCA GTAGCGAACC AACCAATCTC CGGCGCCAAT CTGCGTCGGG

XbaI

~~~~~

121 GCAGGCTCTA GAAACTAA

CGTCCGAGAT CTTTGATT

Fig. 2 d)

4/15

KR)

~~~~~  
NcoI  
~~~~~

GlyValSerMet Ala**LysArg** ThrPheThr SerAspValSer SerTyrLeu GluGlyGln
235 GGGGTATCCA TGGCTAAAAG AACTTTTACT TCTGATGTTT CTTCTTATTT GGAAGGTCAA
CCCCATAGGT ACCGATTTTC TTGAAAATGA AGACTACAAA GAAGAATAAA CCTTCCAGTT
~~~~~  
XbaI  
~~~~~

AlaAlaLysGlu PheIleAla TrpLeuVal ArgGlyArgGly ***
295 GCTGCTAAAG AATTTATTGC TTGGTTGGTT AGAGGTAGAG GTTAGATCTA GA
CGACGATTTC TTAAATAACG AACCAACCAA TCTCCATCTC CAATCTAGAT CT

Fig. 3

5/15

A)

NcoI
~~~~~

GlyValSerMet Ala**ArgAla ArgTyrLys Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTAGAGC TAGATATAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGATCTCG ATCTATATTT TCTTGAAAAT GAAGACTACA AAGAAGAATA  
XbaI  
~~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGATC  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTAG  
 XbaI  
 ~~~~

355 TAGAAAC
 ATCTTTG

B)

NcoI
~~~~~

GlyValSerMet Ala**ArgAsp LeuGlyLys Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTTGAAAAT GAAGACTACA AAGAAGAATA  
XbaI  
~~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGATC  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTAG  
 XbaI  
 ~~~~

355 TAGAAAC
 ATCTTTG

C)

NcoI
~~~~~

GlyValSerMet Ala**ArgAsp LeuAlaLys Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTAGAGA TTTGGCTAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGATCTCT AAACCGATTT TCTTGAAAAT GAAGACTACA AAGAAGAATA  
XbaI  
~~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGATC  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTAG  
 XbaI  
 ~~~~

355 TAGAAAC
 ATCTTTG

Fig. 4 A)-C)

6/15

D)

NcoI
~~~~~

GlyValSerMet Ala**ArgAla ArgAlaLys Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTAGAGC TAGAGCTAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGATCTCG ATCTCGATTT TCTTGAAAAT GAAGACTACA AAGAAGAATA XbaI  
 ~~~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly***
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGATC
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTAG
 XbaI
 ~~~~

355 TAGAAAC  
 ATCTTTG

E)

NcoI  
~~~~~

GlyValSerMet Ala**ArgAla LeuAspLys Arg**ThrPheThr SerAspVal SerSerTyr
 235 GGGGTATCCA TGGCTAGAGC TTTGGATAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT
 CCCCATAGGT ACCGATCTCG AAACCTATTT TCTTGAAAAT GAAGACTACA AAGAAGAATA XbaI
 ~~~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGATC  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTAG  
 XbaI  
 ~~~~

355 TAGAAAC
 ATCTTTG

F)

NcoI
~~~~~

GlyValSerMet Ala**ArgAla LeuAlaLys Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTAGAGC TTTGGCTAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGATCTCG AAACCGATTT TCTTGAAAAT GAAGACTACA AAGAAGAATA XbaI  
 ~~~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly***
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGATC
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTAG
 XbaI
 ~~~~

355 TAGAAAC  
 ATCTTTG

Fig. 4 D)–F)

7/15

G)

NcoI  
 ~~~~~  
 GlyValSerMet Ala**ArgAsp** **LeuGlyLys** **ArgGluAla**Thr PheThrSer AspValSer
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAGAAGCTA CTTTACTTC TGATGTTTCT
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTCTTCGAT GAAAATGAAG ACTACAAAGA
 SerTyrLeuGlu GlyGlnAla AlaLysGlu PheIleAlaTrp LeuValArg GlyArgGly
 295 TCTTATTTGG AAGGTCAAGC TGCTAAAGAA TTTATTGCTT GGTGTTAG AGGTAGAGGT
 AGAATAAACC TTCCAGTTCG ACGATTCTT AAATAACGAA CCAACCAATC TCCATCTCCA
 XbaI
 ~~~~~  
 \*\*\*  
 355 TAGAATCTAG AAAC  
 ATCTTAGATC TTTG

H)

NcoI  
 ~~~~~  
 GlyValSerMet Ala**ProArg** **AspLeuGly** **LysArg**ThrPhe ThrSerAsp ValSerSer
 235 GGGGTATCCA TGGCTCCAAG AGATTGCGT AAAAGAACTT TTACTTCTGA TGTTTCTTCT
 CCCCATAGGT ACCGAGGTTC TCTAAACCCA TTTTCTTGAA AATGAAGACT ACAAAGAAGA
 TyrLeuGluGly GlnAlaAla LysGluPhe IleAlaTrpLeu ValArgGly ArgGly***
 295 TATTTGGAAG GTCAAGCTGC TAAAGAATTT ATTGCTTGGT TGGTTAGAGG TAGAGGTTAG
 ATAAACCTTC CAGTTCGACG ATTTCTTAAA TAACGAACCA ACCAATCTCC ATCTCCAATC
 XbaI
 ~~~~~  
 355 AATCTAGAAA C  
 TTAGATCTTT G

I)

NcoI  
 ~~~~~  
 GlyValSerMet Ala**ArgPro** **LeuGlyLys** **Arg**ThrPheThr SerAspVal SerSerTyr
 235 GGGGTATCCA TGGCTAGACC ATTGGGTAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT
 CCCCATAGGT ACCGATCTGG TAACCCATTT TCTTGAAAAAT GAAGACTACA AAGAAGAATA
 XbaI
 ~~~~~  
 LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGAAT  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTTA  
 XbaI  
 ~~~~~  
 355 CTAGAAAC
 GATCTTTG

Fig. 4 G)-I)

8/15

J)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyLys** **ArgGluAlaGln** ThrPheThr SerAspVal  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAGAAGCTC AAACCTTTTAC TTCTGATGTT  
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTCTTCGAG TTTGAAAATG AAGACTACAA  
 SerSerTyrLeu GluGlyGln AlaAlaLys GluPheIleAla TrpLeuVal ArgGlyArg  
 295 TCTTCTTATT TGGAAGGTCA AGCTGCTAAA GAATTTATTG CTTGGTTGGT TAGAGGTAGA  
 AGAAGAATAA ACCTTCCAGT TCGACGATTT CTAAATAAC GAACCAACCA ATCTCCATCT

XbaI

~~~~~

Gly***
 355 GGTTAGAATC TAGAAAC
 CCAATCTTAG ATCTTTG

K)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyLys** **ArgGluAlaGlu** AlaThrPhe ThrSerAsp  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAGAAGCTG AAGCTACTTT TACTTCTGAT  
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTCTTCGAC TTCGATGAAA ATGAAGACTA  
 ValSerSerTyr LeuGluGly GlnAlaAla LysGluPheIle AlaTrpLeu ValArgGly  
 295 GTTTCTTCTT ATTTGGAAGG TCAAGCTGCT AAAGAATTTA TTGCTTGGTT GGTTAGAGGT  
 CAAAGAAGAA TAAACCTTCC AGTTCGACGA TTTCTTAAAT AACGAACCA CCAATCTCCA

XbaI

~~~~~

355 AGAGGTTAGA ATCTAGAAAC
 TCTCCAATCT TAGATCTTTG

K5)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyLys** **ArgGluAlaGlu** LeuGluLys ArgThrPhe  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAGAAGCTG AATTGGAAAA AAGAACTTTT  
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTCTTCGAC TTAACCTTTT TTCTTGAAAA  
 ThrSerAspVal SerSerTyr LeuGluGly GlnAlaAlaLys GluPheIle AlaTrpLeu  
 295 ACTTCTGATG TTTCTTCTTA TTTGGAAGGT CAAGCTGCTA AAGAATTTAT TGCTTGGTTG  
 TGAAGACTAC AAAGAAGAAT AAACCTTCCA GTTCGACGAT TTCTTAAATA ACGAACCAAC

XbaI

~~~~~

ValArgGlyArg Gly***
 355 GTTAGAGGTA GAGGTTAGAA TCTAGAAAC
 CAATCTCCAT CTCCAATCTT AGATCTTTG

Fig. 4 J)–K5)

9/15

K6)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyArg** **ArgGluAlaGlu** LeuGluLys ArgThrPhe  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAGA AGAGAAGCTG AATTGGAAAA AAGAACTTTT  
 CCCCATAGGT ACCGATCTCT AAACCCATCT TCTCTTCGAC TTAACCTTTT TTCTTGAAAA  
 ThrSerAspVal SerSerTyr LeuGluGly GlnAlaAlaLys GluPheIle AlaTrpLeu  
 295 ACTTCTGATG TTTCTTCTTA TTTGGAAGGT CAAGCTGCTA AAGAATTTAT TGCTTGGTTG  
 TGAAGACTAC AAAGAAGAAT AAACCTTCCA GTTCGACGAT TTCTTAAATA ACGAACCAAC

XbaI

~~~~~

ValArgGlyArg Gly***
 355 GTTAGAGGTA GAGGTTAGAA TCTAGAAAC
 CAATCTCCAT CTCCAATCTT AGATCTTTG

K7)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyGlu** **AlaGluLeuGlu** **LysArg**Thr PheThrSer  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTGAA GCTGAATTGG AAAAAAGAAC TTTTACTTCT  
 CCCCATAGGT ACCGATCTCT AAACCCACTT CGACTTAACC TTTTTTCTTG AAAATGAAGA  
 AspValSerSer TyrLeuGlu GlyGlnAla AlaLysGluPhe IleAlaTrp LeuValArg  
 295 GATGTTTCTT CTTATTTGGA AGGTCAAGCT GCTAAAGAAT TTATTGCTTG GTTGGTTAGA  
 CTACAAAGAA GAATAAACCT TCCAGTTCGA CGATTTCCTA AATAACGAAC CAACCAATCT

XbaI

~~~~~

GlyArgGly***
 355 GGTAGAGGTT AGAATCTAGA AAC
 CCATCTCCAA TCTTAGATCT TTG

L)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyLys** **ArgGluAlaGlu** **AlaGln**Thr PheThrSer  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAGAAGCTG AAGCTCAAAC TTTTACTTCT  
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTCTTCGAC TTCGAGTTTG AAAATGAAGA  
 AspValSerSer TyrLeuGlu GlyGlnAla AlaLysGluPhe IleAlaTrp LeuValArg  
 295 GATGTTTCTT CTTATTTGGA AGGTCAAGCT GCTAAAGAAT TTATTGCTTG GTTGGTTAGA  
 CTACAAAGAA GAATAAACCT TCCAGTTCGA CGATTTCCTA AATAACGAAC CAACCAATCT

XbaI

~~~~~

GlyArgGly***
 355 GGTAGAGGTT AGAATCTAGA AAC
 CCATCTCCAA TCTTAGATCT TTG

Fig. 4 K6)–L)

10/15

L2)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyLys** **ArgGluAlaGlu** **AlaGlnLys** **ArgThrPhe**  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAAA AGAGAAGCTG AAGCTCAAAA AAGAAGCTTTT  
 CCCCATAGGT ACCGATCTCT AAACCCATTT TCTCTTCGAC TTCGAGTTTT TTCTTGAAAA  
 ThrSerAspVal SerSerTyr LeuGluGly GlnAlaAlaLys GluPheIle AlaTrpLeu  
 295 ACTTCTGATG TTTCTTCTTA TTTGGAAGGT CAAGCTGCTA AAGAATTTAT TGCTTGTTG  
 TGAAGACTAC AAAGAAGAAT AAACCTTCCA GTTCGACGAT TTCTTAAATA ACGAACCAAC

XbaI

~~~~~

ValArgGlyArg Gly***

355 GTTAGAGGTA GAGGTTAGAA TCTAGAAAC
 CAATCTCCAT CTCCAATCTT AGATCTTTG

L3)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyArg** **ArgGluAlaGlu** **AlaGlnLys** **ArgThrPhe**  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTAGA AGAGAAGCTG AAGCTCAAAA AAGAAGCTTTT  
 CCCCATAGGT ACCGATCTCT AAACCCATCT TCTCTTCGAC TTCGAGTTTT TTCTTGAAAA  
 ThrSerAspVal SerSerTyr LeuGluGly GlnAlaAlaLys GluPheIle AlaTrpLeu  
 295 ACTTCTGATG TTTCTTCTTA TTTGGAAGGT CAAGCTGCTA AAGAATTTAT TGCTTGTTG  
 TGAAGACTAC AAAGAAGAAT AAACCTTCCA GTTCGACGAT TTCTTAAATA ACGAACCAAC

XbaI

~~~~~

ValArgGlyArg Gly***

355 GTTAGAGGTA GAGGTTAGAA TCTAGAAAC
 CAATCTCCAT CTCCAATCTT AGATCTTTG

L4)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp** **LeuGlyGlu** **AlaGluAlaGln** **LysArgThr** **PheThrSer**  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTGAA GCTGAAGCTC AAAAAAGAAC TTTTACTTCT  
 CCCCATAGGT ACCGATCTCT AAACCCACTT CGACTTCGAG TTTTCTTG AAAATGAAGA  
 AspValSerSer TyrLeuGlu GlyGlnAla AlaLysGluPhe IleAlaTrp LeuValArg  
 295 GATGTTTCTT CTTATTTGGA AGGTCAAGCT GCTAAAGAAT TTATTGCTTG GTTGTTAGA  
 CTACAAAGAA GAATAAACCT TCCAGTTCGA CGATTCTTA AATAACGAAC CAACCAATCT

XbaI

~~~~~

GlyArgGly***

355 GG TAGAGGTT AGAATCTAGA AAC
 CCATCTCCAA TCTTAGATCT TTG

Fig. 4 L2)–L4)

11/15

M)

NcoI

~~~~~

GlyValSerMet Ala**GluArg** **LeuGluArg** **AspLeuGlyLys** **Arg**ThrPhe ThrSerAsp  
 235 GGGGTATCCA TGGCTGAAAG ATTGGAAAGA GATTTGGGTA AAAGAACTTT TACTTCTGAT  
 CCCCATAGGT ACCGACTTTC TAACCTTTCT CTAAACCCAT TTTCTTGAAA ATGAAGACTA  
 ValSerSerTyr LeuGluGly GlnAlaAla LysGluPheIle AlaTrpLeu ValArgGly  
 295 GTTCTTCTT ATTTGGAAGG TCAAGCTGCT AAAGAATTTA TTGCTTGGTT GGTTAGAGGT  
 CAAAGAAGAA TAAACCTTCC AGTTCGACGA TTTCTTAAAT AACGAACCAA CCAATCTCCA

XbaI

~~~~~

ArgGly***

355 AGAGGTTAGA ATCTAGAAAC
 TCTCCAATCT TAGATCTTTG

N)

NcoI

~~~~~

GlyValSerMet Ala**LysGlu** **ArgLeuGlu** **ArgAspLeuGly** **LysArg**Thr PheThrSer  
 235 GGGGTATCCA TGGCTAAAGA AAGATTGGAA AGAGATTTGG GTAAAAGAAC TTTTACTTCT  
 CCCCATAGGT ACCGATTCTT TTCTAACCTT TCTCTAAACC CATTCTTCTG AAAATGAAGA  
 AspValSerSer TyrLeuGlu GlyGlnAla AlaLysGluPhe IleAlaTrp LeuValArg  
 295 GATGTTTCTT CTTATTTGGA AGGTCAAGCT GCTAAAGAAT TTATTGCTTG GTTGTTTGA  
 CTACAAAGAA GAATAAACCT TCCAGTTCGA CGATTCTCTA AATAACGAAC CAACCAATCT

XbaI

~~~~~

GlyArgGly***

355 GGTAGAGGTT AGAATCTAGA AAC
 CCATCTCCAA TCTTAGATCT TTG

O)

NcoI

~~~~~

GlyValSerMet Ala**GluArg** **LeuGluLys** **Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTGAAAG ATTGGAAAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGACTTTC TAACCTTTTT TCTTGAAAAAT GAAGACTACA AAGAAGAATA

XbaI

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGAAT  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTTA  
 XbaI

~~~~~

355 CTAGAAAC
 GATCTTTG

Fig. 4 M)–O)

12/15

P)

NcoI
 ~~~~~  
 GlyValSerMet Ala**LysGlu ArgLeuGlu LysArg**ThrPhe ThrSerAsp ValSerSer  
 235 GGGGTATCCA TGGCTAAAGA AAGATTGGAA AAAAGAACTT TTACTTCTGA TGTTTCTTCT  
 CCCCATAGGT ACCGATTCTT TTCTAACCTT TTTTCTTGAA AATGAAGACT ACAAAGAAGA  
 TyrLeuGluGly GlnAlaAla LysGluPhe IleAlaTrpLeu ValArgGly ArgGly\*\*\*  
 295 TATTTGGAAG GTCAAGCTGC TAAAGAATTT ATTGCTTGGT TGGTTAGAGG TAGAGGTTAG  
 ATAAACCTTC CAGTTCGACG ATTTCTTAAA TAACGAACCA ACCAATCTCC ATCTCCAATC  
 XbaI  
 ~~~~~  
 355 AATCTAGAAA C
 TTAGATCTTT G

Q)

NcoI
 ~~~~~  
 GlyValSerMet Ala**ProGlu ArgLeuGlu ArgAspLeuGly LysArg**Thr PheThrSer  
 235 GGGGTATCCA TGGCTCCAGA AAGATTGGAA AGAGATTGG GTAAAAGAAC TTTTACTTCT  
 CCCCATAGGT ACCGAGGTCT TTCTAACCTT TCTCTAAACC CATTCTTCTG AAAATGAAGA  
 AspValSerSer TyrLeuGlu GlyGlnAla AlaLysGluPhe IleAlaTrp LeuValArg  
 295 GATGTTTCTT CTTATTTGGA AGGTCAAGCT GCTAAAGAAT TTATTGCTTG GTTGTTTGA  
 CTACAAAGAA GAATAAACCT TCCAGTTCGA CGATTCTTA AATAACGAAC CAACCAATCT  
 XbaI  
 ~~~~~  
 GlyArgGly***
 355 GGTAGAGGTT AGAATCTAGA AAC
 CCATCTCCAA TCTTAGATCT TTG

R)

NcoI
 ~~~~~  
 GlyValSerMet Ala**ProGlu ArgLeuGlu LysArg**ThrPhe ThrSerAsp ValSerSer  
 235 GGGGTATCCA TGGCTCCAGA AAGATTGGAA AAAAGAACTT TTACTTCTGA TGTTTCTTCT  
 CCCCATAGGT ACCGAGGTCT TTCTAACCTT TTTTCTTGAA AATGAAGACT ACAAAGAAGA  
 TyrLeuGluGly GlnAlaAla LysGluPhe IleAlaTrpLeu ValArgGly ArgGly\*\*\*  
 295 TATTTGGAAG GTCAAGCTGC TAAAGAATTT ATTGCTTGGT TGGTTAGAGG TAGAGGTTAG  
 ATAAACCTTC CAGTTCGACG ATTTCTTAAA TAACGAACCA ACCAATCTCC ATCTCCAATC  
 XbaI  
 ~~~~~  
 355 AATCTAGAAA C
 TTAGATCTTT G

Fig. 4 P)–R)

13/15

S)

NcoI

~~~~~

GlyValSerMet Ala**GluAla GluAlaArg AspLeuGlyLys Arg**ThrPhe ThrSerAsp  
 235 GGGGTATCCA TGGCTGAAGC TGAAGCTAGA GATTTGGGTA AAAGAACTTT TACTTCTGAT  
 CCCCATAGGT ACCGACTTCG ACTTCGATCT CTAAACCCAT TTTCTTGAAA ATGAAGACTA  
 ValSerSerTyr LeuGluGly GlnAlaAla LysGluPheIle AlaTrpLeu ValArgGly  
 295 GTTCTTCTT ATTTGGAAGG TCAAGCTGCT AAAGAATTTA TTGCTTGGTT GGTAGAGGT  
 CAAAGAAGAA TAAACCTTCC AGTTCGACGA TTTCTTAAAT AACGAACCA CCAATCTCCA  
 XbaI

~~~~~

ArgGly***

355 AGAGGTTAGA ATCTAGAAAC
 TCTCCAATCT TAGATCTTTG

T)

NcoI

~~~~~

GlyValSerMet Ala**ProGlu AlaGluAla ArgAspLeuGly LysArg**Thr PheThrSer  
 235 GGGGTATCCA TGGCTCCAGA AGCTGAAGCT AGAGATTTGG GTAAAAGAAC TTTTACTTCT  
 CCCCATAGGT ACCGAGGTCT TCGACTTCGA TCTCTAAACC CATTTTCTTG AAAATGAAGA  
 AspValSerSer TyrLeuGlu GlyGlnAla AlaLysGluPhe IleAlaTrp LeuValArg  
 295 GATGTTTCTT CTTATTTGGA AGGTCAAGCT GCTAAAGAAT TTATTGCTTG GTTGTTAGA  
 CTACAAAGAA GAATAAACCT TCCAGTTCGA CGATTTCTTA AATAACGAAC CAACCAATCT  
 XbaI

~~~~~

GlyArgGly***

355 GGTAGAGGTT AGAATCTAGA AAC
 CCATCTCCAA TCTTAGATCT TTG

U)

NcoI

~~~~~

GlyValSerMet Ala**GluGlu AlaGluLys Arg**ThrPheThr SerAspVal SerSerTyr  
 235 GGGGTATCCA TGGCTGAAGA AGCTGAAAAA AGAACTTTTA CTTCTGATGT TTCTTCTTAT  
 CCCCATAGGT ACCGACTTCT TCGACTTTT TCTTGAAAAT GAAGACTACA AAGAAGAATA

XbaI

~

LeuGluGlyGln AlaAlaLys GluPheIle AlaTrpLeuVal ArgGlyArg Gly\*\*\*  
 295 TTGGAAGGTC AAGCTGCTAA AGAATTTATT GCTTGGTTGG TTAGAGGTAG AGGTTAGAAT  
 AACCTTCCAG TTCGACGATT TCTTAAATAA CGAACCAACC AATCTCCATC TCCAATCTTA  
 XbaI

~~~~~

355 CTAGAAAC
 GATCTTTG

Fig. 4 s)–U)

14/15

V)

NcoI

~~~~~

GlyValSerMet Ala**GluGlu AlaGluArg AspLeuGlyLys Arg**ThrPhe ThrSerAsp  
 235 GGGGTATCCA TGGCTGAAGA AGCTGAAAGA GATTTGGGTA AAAGAACTTT TACTTCTGAT  
 CCCCATAGGT ACCGACTTCT TCGACTTTCT CTAAACCCAT TTTCTTGAAA ATGAAGACTA  
 ValSerSerTyr LeuGluGly GlnAlaAla LysGluPheIle AlaTrpLeu ValArgGly  
 295 GTTCTTCTT ATTTGGAAGG TCAAGCTGCT AAAGAATTTA TTGCTTGGTT GGTTAGAGGT  
 CAAAGAAGAA TAAACCTTCC AGTTCGACGA TTTCTTAAAT AACGAACCAA CCAATCTCCA

XbaI

~~~~~

ArgGly***

355 AGAGGTTAGA ATCTAGAAAC
 TCTCCAATCT TAGATCTTTG

X)

NcoI

~~~~~

GlyValSerMet Ala**ArgAsp LeuGlyGlu GluAlaGluLys Arg**ThrPhe ThrSerAsp  
 235 GGGGTATCCA TGGCTAGAGA TTTGGGTGAA GAAGCTGAAA AAAGAACTTT TACTTCTGAT  
 CCCCATAGGT ACCGATCTCT AAACCCACTT CTTGACTTT TTTCTTGAAA ATGAAGACTA  
 ValSerSerTyr LeuGluGly GlnAlaAla LysGluPheIle AlaTrpLeu ValArgGly  
 295 GTTCTTCTT ATTTGGAAGG TCAAGCTGCT AAAGAATTTA TTGCTTGGTT GGTTAGAGGT  
 CAAAGAAGAA TAAACCTTCC AGTTCGACGA TTTCTTAAAT AACGAACCAA CCAATCTCCA

XbaI

~~~~~

ArgGly***

355 AGAGGTTAGA ATCTAGAAAC
 TCTCCAATCT TAGATCTTTG

Y)

NcoI

~~~~~

GlyValSerMet Ala**GluGlu AlaGluLeu AlaLysArg**Thr PheThrSer AspValSer  
 235 GGGGTATCCA TGGCTGAAGA AGCTGAATTG GCTAAAAGAA CTTTACTTC TGATGTTTCT  
 CCCCATAGGT ACCGACTTCT TCGACTTAAC CGATTTTCTT GAAAATGAAG ACTACAAAGA  
 SerTyrLeuGlu GlyGlnAla AlaLysGlu PheIleAlaTrp LeuValArg GlyArgGly  
 295 TCTTATTTGG AAGGTCAAGC TGCTAAAGAA TTTATTGCTT GGTGTTAG AGGTAGAGGT  
 AGAATAAACC TTCCAGTTCG ACGATTCTT AAATAACGAA CCAACCAATC TCCATCTCCA

XbaI

~~~~~

355 TAGAATCTAG AAAC
 ATCTTAGATC TTTG

Fig. 4 v)–Y)

15/15

Z)

 NcoI
          ~~~~~

GlyValSerMet Ala**GluGlu** **AlaGluLeu** **GlyLysArg**Thr PheThrSer AspValSer  
235 GGGGTATCCA TGGCTGAAGA AGCTGAATTG GGTAAGAGAA CTTTACTTC TGATGTTTCT  
CCCCATAGGT ACCGACTTCT TCGACTTAAC CCATTTTCTT GAAATGAAG ACTACAAAGA  
SerTyrLeuGlu GlyGlnAla AlaLysGlu PheIleAlaTrp LeuValArg GlyArgGly  
295 TCTTATTGG AAGGTCAAGC TGCTAAGAA TTATTGCTT GGTGGTTAG AGGTAGAGGT  
AGAATAAACC TTCCAGTTCG ACGATTCTT AAATAACGAA CCAACCAATC TCCATCTCCA  
          XbaI  
          ~~~~~

355 TAGAATCTAG AAAC
ATCTTAGATC TTTG

Fig. 4 z)

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/068211

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K1/10 C07K14/605

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y | <p>HODGSON D R W ET AL: "THE SYNTHESIS OF PEPTIDES AND PROTEINS CONTAINING NON-NATURAL AMINO ACIDS"
CHEMICAL SOCIETY REVIEWS, CHEMICAL SOCIETY, LONDON, GB,
vol. 33, no. 7,
1 January 2004 (2004-01-01), pages
422-430, XP008067398
ISSN: 0306-0012
the whole document</p> <p>-----
-/--</p> | 1-15 |

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

24 April 2009

Date of mailing of the international search report

08/05/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/068211

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| Y | <p>WALLACE C J A: "PEPTIDE LIGATION AND SEMISYNTHESIS"
CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB,
vol. 6, no. 4, 1 August 1995 (1995-08-01),
pages 403-410, XP001207188
ISSN: 0958-1669
the whole document</p> | 1-15 |
| Y | <p>MAKINO TOMOHIRO ET AL: "SEMISYNTHESIS OF HUMAN GHRELIN: CONDENSATION OF A BOC-PROTECTED RECOMBINANT PEPTIDE WITH A SYNTHETIC O-ACYLATED FRAGMENT"
BIOPOLYMERS, NEW YORK, NY, US,
vol. 79, no. 5,
5 December 2005 (2005-12-05), pages
238-247, XP009082801
ISSN: 0006-3525
the whole document</p> | 1-15 |
| Y | <p>OKADA Y: "Synthesis of peptides by solution methods"
CURRENT ORGANIC CHEMISTRY, HILVERSUM, NL,
vol. 5, no. 1,
1 January 2001 (2001-01-01), pages 1-43,
XP002445866
ISSN: 1385-2728
the whole document</p> | 1-15 |
| Y | <p>WO 2006/097537 A (NOVO NORDISK AS [DK];
LAU JESPER [DK]; DOERWALD FLORENCIO
ZARAGOZA [DK])
21 September 2006 (2006-09-21)
the whole document</p> | 1-15 |
| Y | <p>WO 2006/097538 A (NOVO NORDISK AS [DK];
LAU JESPER [DK]; DOERWALD FLORENCIO
ZARAGOZA [DK])
21 September 2006 (2006-09-21)
the whole document</p> | 1-15 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/068211

| Patent document
cited in search report | | Publication
date | | Patent family
member(s) | | Publication
date |
|---|---|---------------------|----|----------------------------|--|---------------------|
| WO 2006097537 | A | 21-09-2006 | AU | 2006224536 A1 | | 21-09-2006 |
| | | | CA | 2601784 A1 | | 21-09-2006 |
| | | | CN | 101133082 A | | 27-02-2008 |
| | | | JP | 2008533105 T | | 21-08-2008 |
| | | | KR | 20070120089 A | | 21-12-2007 |
| <hr/> | | | | | | |
| WO 2006097538 | A | 21-09-2006 | AU | 2006224537 A1 | | 21-09-2006 |
| | | | CA | 2596926 A1 | | 21-09-2006 |
| | | | CN | 101128214 A | | 20-02-2008 |
| | | | JP | 2008533106 T | | 21-08-2008 |
| | | | KR | 20070120112 A | | 21-12-2007 |
| | | | US | 2008207507 A1 | | 28-08-2008 |
| <hr/> | | | | | | |